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1. Introduction 
It is reasoned that steroid sulfatase (STS) has a significant role 
in fueling the growth and development of hormone-dependent 
diseases, since the enzyme hydrolyses biologically inactive 
steroid sulfates back to their active unconjugated forms. In 
hormone-dependent breast cancer for example, STS is 
responsible for the conversion of estrone sulfate (E1S) to estrone 
(E1) and also dehydroepiandrosterone sulfate (DHEA-S) to 
DHEA. The formation of DHEA by the STS pathway constitutes 
the production of 90% of androstenediol which is an estrogen 
(ca. 100-fold weaker than estradiol), despite structurally being 
classified as an androgen
1-4
. On this basis, the inhibition of STS 
in this type of cancer might lead to estrogen deprivation and 
hence render therapeutic intervention in the malignancy. 
Once STS had been identified as a target for delivering a 
potential new form of endocrine therapy, considerable attention 
was placed on designing inhibitors of this enzyme over the past 
two decades. One approach was to replace the sulfate group 
(OSO3
-
) of E1S with other sulfate surrogates or mimics that are 
not metabolically labile or hydrolysable by the enzyme in the 
course of competing with E1S for binding to the enzyme active 
site
5-9
. Despite the large number of compounds that have been 
explored in this category, none of these compounds was deemed 
to be potent enough or adequately attractive pharmaceutically for 
further development as an inhibitor of STS.  
 
 
 
 
 
 
Figure 1. Structures of EMATE (estrone 3-O-sulfamate) and the 
non-steroidal STS inhibitor, Irosustat (STX64, BN83495). 
The breakthrough in the design of potent STS inhibitors came 
when the sulfate group of E1S was replaced by a sulfamate 
moiety (-OSO2NH2).
10
 Estrone 3-O-sulfamate (EMATE) (Fig. 1) 
was found to be a highly potent inhibitor with an IC50 of 18 nM 
in a human placental microsomes preparation.
11 
More 
exceptionally, EMATE inhibits STS in a time- and 
concentration-dependent manner, indicating that the mechanism 
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Scheme 1. Nitration of estrone to give predominately 2-nitroestrone (1a) and 4-nitroestrone (2a) which upon sulfamoylation gave their 
respective sulfamates (1) and (2). a) conc. HNO3/glacial acetic acid, 70-75
oC to r.t.; b) NaH/DMF, H2NSO2Cl, 0 
oC.      
  
of action is of an irreversible nature. EMATE is orally active in 
vivo. In one study,
12
 administration at 10mg/kg inhibited rat liver 
STS activity almost completely (99%) when given by the oral or 
subcutaneous route and the inhibition persisted (>95%) for up to 
7 days after a single dosing. However, EMATE was 
unexpectedly shown to be more estrogenic than ethinylestradiol 
when administered orally in rats
13
, although it was revealed 
subsequently that estrogen sulfamates per se do not bind to the 
estrogen receptor
14
. A follow-up study demonstrated that STS has 
a crucial role in regulating the estrogenicity associated with 
EMATE as its estrogenicity is abolished when STS is inhibited 
by co-administration of the non-estrogenic STS inhibitor 
Irosustat (STX64, Fig. 1)
15
. Nonetheless, this unwanted 
estrogenic property rendered the inhibitor undesirable for use as 
an anti-endocrine agent for hormone-dependent cancers. 
However, a congener of EMATE, estradiol 3-O-sulfamate, 
entered human clinical trials in the late 90s as an orally active 
pro-drug for estradiol and good activity has also been reported in 
animal models of endometriosis, as an STS inhibitor.
16 
As EMATE remains an interesting compound because of its 
diverse pharmacological properties, we further expand the SAR 
studies in this work. To this end, we substituted at the 2- and/or 
4-position of A-ring with a nitro group, halogens, alkyl groups 
and a cyano group. The D-ring was modified by removal of the 
C17 carbonyl group. In addition, three compounds were prepared 
which can be loosely described as ‘cyclic sulfamate’ derivatives 
of EMATE as the N-atom of the sulfamate group of EMATE is 
bonded to either the 2- or 4-position of the steroid scaffold. The 
synthesized compounds were tested for STS inhibitory activity in 
a placental microsomes preparation and also in MCF-7cells. 
 
2. Chemistry 
2-Nitroestrone (1a, Scheme 1) and 4-nitroestrone (2a, Scheme 
1) were prepared by nitrating estrone according to the method of 
Tomson and Horwitz.
17
 Compound 2a came out of the reaction 
mixture overnight and was deposited as a yellow precipitate 
whereas 1a was isolated from the filtrate and purified by several 
cycles of recrystallization. An earlier method was employed for 
the sulfamoylation of these nitrated estrones (Scheme 1). This 
involved treating a solution of 1a or 2a in anhydrous N,N-
dimethylformamide (DMF) with sodium hydride (NaH) followed 
by addition of a freshly concentrated solution of sulfamoyl 
chloride in toluene, which was prepared according to the method 
of Woo et al.
 18
 
The synthesis of 2- and 4-alkylestrone was carried out as 
described by Patton.
19
 A Claisen rearrangement of the 
intermediate 3-O-(2-propenyl)estrone (3, Scheme 2) to give 2- 
and 4-(2-propenyl)estrone was straightforward although the 
separation of the geometrical isomers obtained was particularly 
cumbersome. 2-(2-Propenyl)estrone (4a, Scheme 2) was only 
isolated in poor yield upon repeated and slow (over two weeks) 
fractional recrystallizations of the crude material in diethyl ether. 
Despite careful fractional recrystallization of the crude 4-(2-
propenyl)estrone (5a, Scheme 2), this isomer could not be 
obtained in a pure state and the best sample in our hands 
contained approximately 25% of 4a as shown by 
1
H NMR. When 
a mixture of 2-(2-propenyl)- and 4-(2-propenyl)estrones in DMF 
was heated with 3-bromoprop-1-ene in the presence of NaH, a 
mixture of the 3-O-(2-propenyl) derivatives of 4a and 5a (6 and 7 
respectively, Scheme 2) was obtained. When this mixture was 
subjected to Claisen rearrangement conditions 2,4-di-(2-
propenyl)estrone (8a, Scheme 2) was obtained in good yield. 
Compounds 4a, 5a and 8a were sulfamoylated in the same 
manner as 1a to give sulfamates 4, 5 and 8 respectively.   
Initially, 2-n-propyl- (9), 4-n-propyl- (10) and 2,4-di-n-propyl- 
(11) EMATEs were obtained by sulfamoylating the 
corresponding parent phenols that were obtained upon 
hydrogenation of the (2-propenyl)estrones. However, it was 
found subsequently that the sulfamate group is not labile to the 
hydrogenation conditions employed and hence 2-(2-propenyl)- 
(4), 4-(2-propenyl)-(5) and 2,4-n-di-(2-propenyl)-(8) EMATEs 
were hydrogenated directly to give respectively 2-n-propyl- (9) 
and 4-n-propyl- (10) and 2,4-di-n-propyl- (11) EMATEs 
(Scheme 3). It is worth noting that while repeated attempts to 
recrystallize 5 had failed to afford a pure sample other than a 
batch that was co-recrystallized with 4, pure 10 without 
contaminating by isomer 9 was obtained when the crude material 
was recrystallized from ethyl acetate/hexane.  
Scheme 2. Synthesis of 2-(2-propenyl)estrone 3-O-sulfamate (4), 4-(2-propenyl)estrone 3-O-sulfamate (5) and 2,4-di-(2-propenyl)estrone 3-
O-sulfamate (8) via various intermediates (3), (4a), (5a), (6), (7) and (8a).  a) NaH/DMF, 3-bromoprop-1-ene, 80 0C, 2h; b) N,N-
diethylaniline, N2, reflux, 6 h; c) NaH/DMF, H2NSO2Cl, 0 
oC.      X = OSO2NH2    * contains ca. 25% of 4a as shown by 
1H NMR;    
** impure, contains 6. 
Scheme 3. Hydrogenation of (2-propenyl)estrone sulfamates (4), 
(5) and (8) to give respectively 2-n-propylestrone 3-O-sulfamate 
(9), 4-n-propylestrone 3-O-sulfamate (10) and 2,4-di-n-
propylestrone 3-O-sulfamate (11).  a) Pd-C(10%)/abs. EtOH, H2, 
50 p.s.i.     X = OSO2NH2       * impure 
 
 
 
 
 
 
Scheme 3. Hydrogenation of (2-propenyl)estrone sulfamates (4), 
(5) and (8) to give respectively 2-n-propylestrone 3-O-sulfamate 
(9), 4-n-propylestrone 3-O-sulfamate (10) and 2,4-di-n-
propylestrone 3-O-sulfamate (11).  a) Pd-C(10%)/absolute EtOH, 
H2, 50 p.s.i.     X = OSO2NH2       * impure 
 
 
 
 
 
 
 
 
 
The route to 2-fluoroestrone 12b (Scheme 4) was described by 
Page et al.
 20
 and involved an electrophilic fluorination of estrone 
by Umemoto’s reagent, N-fluoropyridinium triflate, followed by 
a direct acetylation using acetic anhydride in pyridine in order to 
facilitate purification of the fluorinated estrone derivative 12a. In 
our hands, a low yield (12%, after recrystallization) of 12a was 
obtained from estrone, primarily as a result of competing 
formation of other by-products (presumably 2- and 4-
chloroestrones). Upon deacetylation of 12a using potassium 
carbonate in methanol, 2-fluoroestrone (12b) was obtained which 
was purified by preparative TLC (45% yield). Sulfamoylation of 
12b with sulfamoyl chloride in the presence of 2,6-di-tert-butyl-
4-methylpyridine (DBMP) as base gave 2-fluoroEMATE (12) in 
57 % yield. 
Several procedures for preparing the 2-chloro, 2-bromo, 2-
iodo and 2-cyano derivatives of estrone are available but few of 
these are regioselective, ie. functionalizing predominantly at 
position 2. Compounds 15b – 18b (Scheme 4) were prepared as 
described by Page et al.
 20
 The direct arene thalliation with thallic 
trifluoroacetate (or triacetate) in trifluoroacetic acid and 
subsequent displacement of the estrogen-thallium (III) 
bis(trifluoroacetate) intermediate with copper (I) halides (halides 
= Cl, Br, I) and copper (I) cyanide gave a convenient 
regioselective method for the synthesis of 2-substituted estrones. 
Sulfamoylation of compounds 15b – 18b was carried out in a 
similar manner to 1a to give the sulfamates 15 – 18. 
Slaunwhite and Neely
21
 reported that 4-bromoestrone (19a) 
was obtained in high yield when a solution of estrone in aqueous 
acetic acid (contained 15-20% of water) was treated with 5% v/v 
of bromine in acetic acid in the presence of a small amount of 
powdered iron. In contrast, when aqueous acetic acid was 
replaced with glacial acetic acid, the authors reported that the 
bromination reaction yielded predominately 2-bromoestrone. 
However, in our hands, 19a was obtained as the main product 
when a solution of estrone in glacial acetic acid (Scheme 4) was 
brominated under the conditions used. The sulfamoylation of 19a 
to give sulfamate 19 was carried out in the same manner as 1a. 
The carbonyl group of estrone was reduced to a methylene 
group under Wolff-Kishner conditions for reduction of steroid 
ketones.
22
 The product 3-hydroxy-1,3,5(10)-estratriene (20a, 
Scheme 5) was sulfamoylated in the same manner as 1a to give 
1,3,5(10)estratriene 3-O-sulfamate (20). 
The chemistry developed by Andersen et. al.
23,24
 for the 
synthesis of 1,2,3-benzoxathiazole-2,2-dioxides was applied to 
the synthesis of ‘cyclic sulfamates’ (21), (22) and (23). The 
starting 2-amino (21a) and 4-aminoestrone (23a) were easily 
Scheme 4. Synthesis of 2- and 4-substituted derivatives of EMATE. a) N-fluoropyridinium triflate/1,2-trichloroethane, reflux, N2, 24 h; b) 
pyridine/acetic anhydride, reflux, 2 h; c) K2CO3/MeOH, reflux, 3 h; d) DBMP/DMF, H2NSO2Cl, 0 
oC; e) (CH3CO)2O/pyridine, reflux, 2 h; f) 
Tl(OCOCF3)3/CF3COOH, 0 – 5 
oC, N2, 24 h; g) CuX/1,4-dioxane (X = Cl, Br, I, CN); h) NaH/DMF, H2NSO2Cl, 0 
oC; i) Br2/glacial acetic 
acid/powdered Fe, r.t..     X = OSO2NH2 
        
 
Scheme 5. Wolff-Kishner reduction of estrone and synthesis of 
sulfamate 20. a) NH2NH2·H2O, KOH/diethylene glycol, reflux; b) 
NaH/DMF, H2NSO2Cl, 0 
oC.    X = OSO2NH2 
          
Scheme 6. Synthesis of ‘cyclic’ derivatives of EMATE. a) Pd/C(10%)/CH2Cl2, H2 (balloon), 20 h; b) anhydrous pyridine, 0 
oC, TsCl; 
c) Et3N/CH2Cl2, SO2Cl2/CH2Cl2 (0.5 M), -78 
oC; d) MeCN/aqueous KF, reflux, 3 h; e) NaH/DMF, MeI, 90 oC, 3 h.  
 
obtained by hydrogenating 2-nitro- (1a) and 4-nitroestrone (2a) 
respectively in the presence of palladium-charcoal. Whilst 23a 
appears to be stable, decomposition of 21a upon standing and 
exposure to air at room temperature was observed, as reported by 
Kraychy,
25
 and hence 21a was used without further purification. 
The selective N-tosylation of 21a and 23a with tosyl chloride to 
give 2- (21b) and 4-tosylamidoestrone (23b) respectively was 
carried out in the presence of pyridine using conditions reported 
by Kurita
26
 for the selective N-tosylation of o-aminophenol. Ring 
closure of 21b and 23b to give the respective cyclic compounds 
21c and 23c was carried out with sulfuryl chloride in 
dichloromethane. Removal of the protecting tosyl group of 21c 
and 23c with an aqueous solution of potassium fluoride gave 21 
and 23 in moderate to good yields. Deprotonation of 21 in DMF 
with NaH followed by refluxing with methyl iodide gave the N-
methylated derivative 22 
3. Biological Results and Discussion 
Table 1 
Inhibition of STS in a placental microsomes (P.M.) preparation and in MCF-7 
cells by derivatives of EMATE 1, 2, 4, 5, 8 – 12, 15 – 18, 19 and 20, and 
‘cyclic sulfamates’ 21 – 23.  
 
 
 
 
 
 
 
 
a Unless stated otherwise, errors are < 5% of the reported value (from  
  triplicate experiments). 
b Ref.11, cf. 0.4 nM 27, 9.1 nM 28 
c Ref.27  
d IC50 0.065 nM 
29  
*contains 25% of 2-(2-propenyl)EMATE (4) 
- not applicable 
nd: not determined 
 
 The in vitro inhibitory activities of compounds against STS in 
a placental microsomes preparation are shown in Table 1. We 
reported the biological activity of 1, 2, 4, 5, 8 - 11 earlier
27
 but 
herein report full experimental data. Importantly, in order to 
assess the ability of compounds to cross the cell membrane and 
inhibit STS under conditions that closely resemble the 
tissue/physiological situation, we newly evaluate compounds 
(apart from 21 – 23) in intact MCF-7 cells. The results are shown 
in Table 1. 
 We have demonstrated repeatedly in previous work that the 
STS inhibitory activity of an aryl sulfamate in general can be 
increased by either placing an electron-withdrawing group 
adjacent to the sulfamate group,
30-38
 or by having the sulfamate 
group attached to an aryl ring system such as coumarin,
39-41
 that 
renders the parent phenol a better leaving group by virtue of 
lowering its pKa value. With the exception of 1, the same effect is 
observed for 2, 12, 15 – 18 when tested in a placental microsome 
preparation since these sulfamates were found to be more potent 
than EMATE as STS inhibitors. A similar trend is observed for 
STS inhibition in MCF-7 cells with the exception of 17 and 18 
which are comparable and slightly weaker inhibitors than 
EMATE respectively. As shown in Table 2, the pKa values of 
various substituted phenols, 2-nitroestrone (1a) and 4-
nitroestrone (2a) are between 1 and 3 log units lower than that of 
an unsubstituted phenol such as estrone. We postulate in general 
that this lowering of pKa value of the parent phenol improves its 
leaving group ability which in return facilitates the inactivation of 
the enzyme by its corresponding sulfamate through 
sulfamoylation of an essential amino acid residue in the active 
site.  
 
Table 2 
pKa values of various phenols, 2-nitroestrone (1a) and 4-nitroestrone (2a) as 
determined by ACD/Labs Software v 11.02. 
Compound pKa 
Phenol 9.86  0.10 
2-Fluorophenol 8.71  0.10 
2-Chlorophenol 8.50  0.10 
2-Bromophenol 8.43  0.10 
2-Iodophenol 8.52  0.10 
2-Cyanophenol 7.17  0.10 
2-Nitrophenol 7.14  0.14 
1a 7.43  0.40 
2a 7.10  0.40 
 
Unexpectedly, 2-nitroEMATE (1) is less potent than EMATE as 
an STS inhibitor while its congener 4-nitroEMATE (2) is 
significantly more potent than EMATE despite their parent 
phenols sharing a similar calculated pKa value of around 7 (Table 
1). We reason that this result might be due to potential 
interaction(s) between the nitro group at the 2-position and the 
sulfamate group at the 3-position in 1, rendering the sulfamate 
group either less stable chemically and/or less effective in 
inactivating the enzyme via sulfamoylation.
27
 Due to steric 
hindrance presented by the neighbouring hydrogen atom(s) at C6, 
the nitro group at the 4-position of 2 might not be amenable to 
having potential interactions(s) with its sulfamate group at the 3-
position, rendering it relatively more stable and effective in 
sulfamoylating the enzyme.
27
 Another possible explanation for 
the higher STS inhibitory activity observed for 2 is that its 4-nitro 
group might interact with the enzyme active site favorably. A 
recent study carried out by Taylor et al.
42
 has shown that 2-
nitroestrone (1a, IC50 = 17 M) was 7-fold less potent in a 
purified STS assay as an STS inhibitor than its 4-nitro isomer 
(2a, IC50 2.4 M). The authors attributed this finding to factors 
such as hydrogen bonding ability and/or other interactions of the 
nitro group placed at the 4-position of the steroid ring. Favorable 
interactions between a substituent and neighboring amino acid 
residue(s) in the active site have been observed before. For 
instance, 2-difluoromethylestrone 3-O-sulfamate was found to 
have an IC50 of 100 pM against STS in a placental microsomes 
preparation.
28
 It has been reasoned that the electron-withdrawing 
effect of the 2-fluoromethyl group as well as the potential of the 
fluorine atoms in forming hydrogen bond with residues lining the 
Compd R1
 R2
 P.M. 
IC50 (nM)
a 
MCF-7 
IC50 (nM)
a/ 
% inhibitiona 
EMATE H H 18b 0.83
d 
1 NO2 H 70
c 8.3 
2 H NO2 0.8
c 0.01 
4 2-propenyl H     2500c 37 
  5* H  2-
propenyl 
9000c 153 
8 2-propenyl     2-propenyl >10,000c <10%@10M 
9 n-propyl H   2900c 236 
10 H n-propyl >10,000c <10%@10M 
11 n-propyl n-propyl >10,000c <10%@10M 
12 F H 5.6 0.62 
15 Cl H 3.4 0.44 
16 Br H 1.65 0.11 
17 I H 6.1 0.81 
18 CN H 5.2 1.2 
19 H Br 1200 42 
20 - 199 97%@0.01M 
21 - >10,000 nd 
22 - > 10,000 nd 
23 - >10,000 nd 
 
  
 
catalytic active site of STS are contributive factors to the high 
potency observed. 
 Derivatives 12 and 15-17, which are substituted with a 
halogen at the 2-position, are clearly more potent STS inhibitors 
than EMATE when tested in placental microsomes. The activities 
of these halogenated compounds are of the same order of 
magnitude, although the bromo congener is the most potent 
inhibitor of the series with an IC50 of 1.65 nM. When tested in 
MCF-7 cells, only 15 and 16 are significantly more potent than 
EMATE. The activities of 12 and 17 are considered to be similar 
to that of EMATE. Given the pKa value of their respective parent 
phenol is similar at around 8.5 (Table 2), other factors such as the 
lipophilicity of compounds might influence the different in vitro 
activity observed. In general, a more lipophilic inhibitor has a 
higher affinity for the enzyme active site and hence exhibits 
better inhibitory activity than one that is less lipophilic. As fluoro 
derivative 12 is the least lipophilic, whereas iodo derivative 17 is 
the most lipophilic, one might expect the potency of these 2-
halogenated derivatives of EMATE against STS to be in an 
ascending order from 12 to 17. However, the fact that 17 
(IC50(P.M.) = 6.1 nM and IC50(MCF-7) = 0.81 nM, Table 1) is a 
weaker STS inhibitor than its bromo congener 16 (IC50(P.M.) = 
1.65 nM and IC50(MCF-7) = 0.11 nM, Table 1) suggests that steric 
hindrance rendered by the bulkier iodine atom of 17 interferes 
with the binding of its sulfamate group to the catalytic site, 
preventing the inhibitor from inactivating the enzyme effectively. 
Hence, for derivatives of EMATE substituted at the 2-position 
with a halogen, it appears that having a bromine atom is most 
optimized for STS inhibition and binding of the inhibitor to STS 
active site. It is worth noting that a recent study carried out by Lu 
et al.
43
 provides evidence for weak halogen-oxygen bonding 
between halogenated ligands and protein kinases, with the 
strength of the interactions calculated decreases in the order H ≈ I 
> Br > Cl. Although it is much weaker than hydrogen bonding, 
the authors argue that halogen-bonding may play an important 
role in inhibitor recognition and binding. With reference to our 
work here, it is not clear whether halogen-oxygen bonding plays 
a role in the binding of halogenated EMATEs to the STS active 
site. 
 While brominating EMATE at the 2-position results in a 
highly potent STS inhibitor 16, substitution of EMATE at the 4-
position with a bromine atom is detrimental to activity. As shown 
in Table 2, the IC50 values of the isomer 4-bromoEMATE (19) 
against STS in placental microsomes (1200 nM) and MCF-7 cells 
(42 nM) are a few orders of magnitude lower than those of 
EMATE (IC50(P.M.) = 18 nM and IC50(MCF-7) = 0.83 nM) and 16 
(IC50(P.M.) = 1.65 nM and IC50(MCF-7) = 0.11 nM). Given the 
electron-withdrawing effect of the bromine atom in 16 and 19 is 
expected to be similar, it is possible that any beneficial 
interaction provided by a bromine atom is better recognized by 
the enzyme active site when it is substituted at the 2-position of 
EMATE.  
 In placental microsomes, the IC50 value observed for 20 (17-
deoxyEMATE, IC50 = 199 nM, Table 2) is 11-fold higher than 
that of EMATE (IC50 = 18 nM, Table 2). Hence, removal of the 
17-carbonyl group of EMATE significantly reduces STS 
inhibitory activity, demonstrating an important role for hydrogen 
bonding between the D-ring of steroidal inhibitor and the active 
site. However, not all disruptions made to the D-ring of EMATE 
are detrimental. Previous work has shown that 3-sulfamoyloxy-
16,17-seco-estra-1,3,5(10)-triene-16,17-imide, a steroid-like 
derivative of EMATE, is equipotent to EMATE as an STS 
inhibitor.
11 
 As shown in Table 1, all derivatives of EMATE substituted at 
the 2- and/or 4-positions with an aliphatic group are weak STS 
inhibitors. However, substitution of 2-propenyl or n-propyl group 
at the 2-position is better tolerated by the enzyme than that at the 
4-position as shown by the higher inhibitory activity observed for 
4 (IC50(P.M.) = 2500 nM and IC50(MCF-7) = 37 nM) and 9 (IC50(P.M.) = 
2900 nM and IC50(MCF-7) = 236 nM) than 5 (IC50(P.M.) = 9000 nM 
and IC50(MCF-7) = 153 nM) and 10 (IC50(P.M. and MCF-7)s: >10,000 
nM). One possible reason for this difference in activity between 
2- and 4-alkylated derivatives is the steric hindrance exerted by 
the hydrogen atom(s) at the neighboring C6 atom on the 
substituent at the 4-position, restricting the rotation of alkyl 
groups and hence making them less tolerated by the enzyme. 
When considering substitution made at either the 2- or 4-positon 
alone, apparently there is no significant difference in the 
inhibitory activities observed between the more rigid 2-propenyl 
group and the more flexible n-propyl group (4 vs 9, and 5 vs 10), 
suggesting that both groups are not well tolerated by the enzyme 
active site. Clearly, the steric hindrance poses by these groups is 
expected to be even more prominent when they are substituted at 
both the 2- and 4-positions of EMATE (8 and 11). The shielding 
of the sulfamate group from interacting effectively with the 
catalytic site of the enzyme by these aliphatic substituents might 
explain the overall weak STS inhibitory activity observed for 
compounds 4, 5, 8, and 9 - 11. It is interesting to note that 2-
methylEMATE, a smaller chain  relative of 9, was found to be 
even a weaker STS inhibitor with an IC50 of over 10,000 nM in a 
placental microsomes preparation.
28
 Despite a methyl group often 
being viewed to be isosteric and isolipophilic with the chlorine 
atom,
44
 which means steric hindrance might not be the main 
detrimental factor, the hyperconjugative electron-donating effect 
of the methyl group of 2-methylEMATE on the A-ring, as 
reflected by the calculated pKa of 10.31  for 2-methylphenol, 
might render the sulfamate group less effective in inactivating 
STS via sulfamoylation. The best 2-alkyl derivative of EMATE 
reported to date as an inhibitor of STS is 2-ethylEMATE. Its IC50 
in a placental microsomes preparation was found to be 820 nM.
45  
 We postulated in previous work several mechanisms through 
which an aryl sulfamate (eg. EMATE) might inhibit STS.
7,40
 Two 
of which are i) nucleophilic attack on the sulfur atom of the 
sulfamoyl group by the hydrated form of formylglycine residue 
(gem-diol) in the STS active site; and ii) specific or non-specific 
sulfamoylation by an aryl sulfamate of an essential nucleophilic 
amino acid residue in the STS active site. Andersen et al.
23,24
 
reported that some 1,2,3-benzoxathiazole 2,2-dioxides (e.g. 22 
and 23, Figure 2) are reactive toward nucleophiles. When the 
candidate was 3-tosyl-1,2,3-benzoxathiazole 2,2-dioxides (22), 
hydroxide ion and amines attacked the endocyclic sulfur atom of 
cyclic sulfamate, resulting in ring opening. Given this 
observation, we prepared the cyclic sulfamate derivatives of 
EMATE, 19, 20 and 21 (Scheme 6). The rationale is that if a 
nucleophilic residue in the enzyme active site attacks the sulfur 
atom of cyclic sulfamate, these cyclic sulfamates might exhibit 
STS inhibitory activities. In contrast to acyclic sulfamates like 
EMATE, where we expect the parent phenol to be released upon 
sulfamoylation of the enzyme by the sulfamate group, there 
Figure 2. Structures of 3-methyl-1,2,3-benzoxathiazole 2,2-
dioxide (22) and 3-tosyl-1,2,3-benzoxathiazole 2,2-dioxide (23) 
should be no release of estrone expected for cyclic sulfamates 19, 
20 and 21 upon ring opening as their steroid skeleton should 
remain attached to the sulfamoyl group via its N-atom. 
Unfortunately, as shown in Table 2, none of these cyclic 
sulfamates was found to be active against STS. It is possible that 
the cyclic sulfamate moiety of 19, 20 and 21 did not bind or align 
in a similar manner to the sulfamate group of EMATE in the 
catalytic site of STS for potential attack by a nucleophilic amino 
acid. Alternatively, the lack of an unsubstituted sulfamate group 
in 19, 20 and 21 might be the culprit, as it has been shown earlier 
that a free sulfamate group (H2NSO2OAr) is prerequisite for 
potent irreversible inhibition of STS.
10,41,46 
 
4. Conclusions 
A series of 2- and/or 4-substituted derivatives of EMATE was 
prepared and its 17-carbonyl group removed. The following 
general order of potency against STS is observed: The 4-NO2 > 
2-halogens, 2-cyano > unsubstituted (EMATE) > 17-
deoxyEMATE > 2-NO2 > 4-bromo > 2-(2-propenyl), 2-n-propyl 
> 4-(2-propenyl), 4-n-propyl > 2,4-(2-propenyl) = 2,4-di-n-
propyl. The general SAR derived from the studies indicates that 
EMATE derivatives that have electron-withdrawing substituents 
(4-nitro, 2-halogens and 2-cyano) on the A-ring, show a higher 
STS inhibition than EMATE in vitro, with the exception of 
having a nitro group at the 2-position which results in a 
significant lowering in potency. This reinforces the relationship 
between the pKa value/leaving group ability of a parent phenol 
and the potential of an aryl sulfamate in the inactivation of STS, 
presumably through sulfamoylation of an essential amino acid 
residue. The introduction of a bromine at the 4-position of or 
removal of the 17-carbonyl group of EMATE is detrimental to 
activity. The derivatives resulted are significantly weaker STS 
inhibitors than EMATE. When the 2- and/or 4-positions of the A-
ring are substituted with the bulkier 2-propenyl or 2-n-propyl 
groups, the potent STS inhibition shown by EMATE is 
significantly reduced or abolished. For an aryl sulfamate to be 
effective as an STS inhibitor, inter alia, its sulfamate group must 
be presented to the catalytic site of the enzyme unhindered and 
the required interactions with various key amino acid residues in 
the active site uninterrupted. Three cyclic sulfamates prepared are 
not STS inhibitors as hoped. This further confirms that a free or 
N-unsubstituted sulfamate group (H2NSO2O-) is a prerequisite 
for potent and irreversible inhibition of STS as shown by 
inhibitors like EMATE and Irosustat. 
 
5. Experimental 
5.1 General 
All chemicals were purchased from either Aldrich Chemical 
Co. (Gillingham, UK) or Lancaster Synthesis (Morecombe, 
Lancashire, UK).  All organic solvents of A.R. grade were 
supplied by Fisher Scientific (Loughborough, UK). Anhydrous 
N,N-dimethylformamide (DMF), dichloromethane and pyridine 
were purchased from Aldrich.  Sulfamoyl chloride was prepared 
by an adaptation of the method of Appel and Berger
47
 and was 
stored as a solution under N2 in toluene as described by Woo et 
al.
48 
Thin layer chromatography (TLC) was performed on pre-
coated plates (Merck TLC aluminium sheets silica gel 60 F254, 
Art. No. 5554). Product(s) and starting material were detected by 
viewing under UV light and/or treating with a methanolic 
solution of phosphomolybdic acid followed by heating. Flash 
column chromatography was performed using gradient elution 
(solvents indicated in text) on wet-packed silica gel (Sorbsil 
C60). IR spectra were determined by a Perkin-Elmer 782 infrared 
spectrophotometer, and peak positions are expressed in cm
-1
.
  1
H, 
13
C and 
19
F NMR spectra were recorded with either a Jeol Delta 
270 MHz or a Varian Mercury VX 400 MHz spectrometer.  
Chemical shifts are reported in parts per million (ppm, ) relative 
to tetramethylsilane (TMS) as an internal standard. Coupling 
constants J are given in Hz.  Mass spectra were recorded at the 
Mass spectrometry Service Center, University of Bath. FAB 
mass spectra were measured using m-nitrobenzyl alcohol as the 
matrix. Elemental analyses were performed by the Microanalysis 
Service, University of Bath. Melting points were determined 
using a Reichert-Jung Thermo Galen Kofler block and are 
uncorrected. HPLC was undertaken using a Waters 717 machine 
with Autosampler and PDA detector. The column used, 
conditions of elution and purity of sample are as indicated for 
each compound analysed. 
 
5.2 Biology 
 Assays were performed essentially as described previously.
49
 
The ability of the compounds synthesized to inhibit STS activity 
was examined using placental microsomal preparations. Placental 
microsomes (100,000 g fraction) were prepared from a sulfatase-
positive human placenta from a normal-term pregnancy.
50
 To 
determine the IC50s for the inhibition of STS, activity was 
measured in the presence of the inhibitor (0.1 nM–10 M) using 
[
3
H]E1S (4x10
5
 dpm) adjusted to 20 M with unlabelled 
substrate. After incubation of the substrate-inhibitor with 
placental microsomes (125g of protein/mL) for 30 min, the 
product formed was isolated from the mixture by extraction with 
toluene (4 mL), using [4-
14
C]E1 to monitor procedural losses. 
 Intact monolayers of MCF-7 breast cancer cells were 
incubated for 20 h at 37 °C with [
3
H]E1S (5 pmol, 7 x 10
5
 dpm, 
60 Ci/mmol, NEN Du Pont, Boston, MA) in serum-free minimal 
essential medium (2.5 mL) with or without inhibitors (0.1-10 
µM). After incubation, medium (1 mL) was removed and product 
estrone separated from E1S by solvent partition using toluene 
(4 mL). [
14
C]Estrone (7 x 10
3
 dpm, 52 mCi/mmol. Amersham 
International, U.K.) was used to correct for procedural losses. An 
aliquot of the organic phase was added to scintillation fluid and 
the 
3
H and 
14
C content measured by scintillation spectrometry. 
The mass of E1S hydrolyzed was calculated from the 
3
H counts 
detected (corrected for the volume of medium and organic 
solvent used and for recovery of 
14
C counts) and the specific 
activity of the substrate. 
 
5.3 Syntheses 
 
5.3.1. 2-Nitroestrone (1a) and 4-Nitroestrone (2a) 
 These were prepared according to the method as described by 
Tomson and Horwitz
17
.   
 
5.3.2.  2-Nitroestrone 3-O-sulfamate (1) 
 To a solution of 1a (2.50 g, 7.94 mmol) in anhydrous DMF 
(100 mL) at ice/water temperature and under an atmosphere of 
nitrogen was added sodium hydride (60% dispersion in mineral 
oil, 350 mg, 8.73 mmol). After the evolution of hydrogen had 
ceased, sulfamoyl chloride in toluene (ca. 0.68M, 18 mL) was 
introduced and the resulting mixture was stirred at room 
temperature for 3 h.  The reaction mixture was then concentrated 
in vacuo and the resulting residue in ethyl acetate (200 mL) was 
washed with hydrochloric acid (0.1M, 150 mL) and then brine (4 
x 100 mL). After drying (MgSO4), filtration and evaporation of 
the organic layer (water bath temperature  40 
o
C), the yellow 
residue (3.1 g) obtained was fractionated by flash 
chromatography (ethyl acetate/hexane, 1:2 to 1:1, gradient). The 
second fraction that collected (yellow syrup, 730 mg, 1.85 mmol, 
23%) was recrystallized from ethyl acetate/hexane (1:2) to give 1 
as creamy needles (459 mg). Mp 158-162 
o
C (dec.); Rf (ethyl 
acetate/hexane, 1:1) 0.28, c.f. Rf 0.58 (1a); 
1
H NMR (270 MHz, 
CDCl3)  0.93 (3H, s, CH3), 1.2-3.1 (15H, m), 5.25 (2H, br s, 
exchanged with D2O, OSO2NH2), 7.29 (1H, s, C4H) and 7.98 
(1H, s, C1H); LRMS (FAB
+
) m/z (%) 548 [30, (M+H+NBA)
+
], 
395 [100, (M+H)
+
], 378 [37, (M-NH2)
+
], 315 [30, (M+H-
H2NSO2)
+
], 298 [25, (M-H2NSO2O)
+
]; LRMS (FAB
-
) m/z (%) 
546 [10, (M-H+NBA)
-
], 393 [100, (M-H)
-
], 314 [30, (M-
H2NSO2)
-
], 96 [50, (H2NSO2O)
-
]. Found: C, 54.6; H, 5.58; N, 
7.10. C18H22N2O6S requires C, 54.81; H, 5.62; N, 7.10%.  
 
5.3.3.  4-Nitroestrone 3-O-sulfamate (2) 
 This was prepared from 2a (1.0 g, 3.17 mmol) in a similar 
manner to the preparation of 1. The crude product was 
fractionated by flash chromatography (chloroform/ethyl acetate, 
4:1 to 2:1, gradient) and the second fraction that collected (pale 
yellow syrup, 300 mg, 761 mol, 24%) was recrystallized from 
chloroform/hexane (1:1) to give 2 as pale yellow crystals (167 
mg). Mp 176-178 
o
C; Rf (chloroform/ethyl acetate, 4:1) 0.20, c.f. 
Rf 0.49 (2a); 
1
H NMR (270 MHz, CDCl3)  0.93 (3H, s, CH3), 
1.2-3.0 (15H, m), 5.1 (2H, br s, exchanged with D2O, OSO2NH2), 
7.43 (1H, d, J ~ 9 Hz, ArH) and 7.49 (1H, d, J = 9 Hz, ArH); 
LRMS (FAB
+
) m/z (%) 395 [100, (M+H)
+
]; LRMS (FAB
-
) m/z 
(%) 393 [100, (M-H)
-
], 314 [72, (M-H2NSO2)
-
], 96 [38, 
(H2NSO2O)
-
]. Found: C, 54.6; H, 5.57; N, 7.02. C18H22N2O6S 
requires C, 54.81; H, 5.62; N, 7.10%. HPLC: Spherisorb ODS2 
(5m, 25 x 4.6 cm), methanol/water (75:25), 1mL/min, max 281 
nm, tR = 3.82 min. 
 
5.3.4.  3-O-(2-Propenyl)estrone (3) 
 To a solution of estrone (10.0 g, 36.98 mmol) in DMF (70 
mL) at ice/water temperature was treated cautiously with sodium 
hydride in portions (60% in mineral oil, 1.63 g, 40.68 mmol).  
The resulting mixture was heated with 3-bromoprop-1-ene (3.9 
mL, 44.38 mmol) at 80 
o
C for 2 h and then stirred under an 
atmosphere of nitrogen at room temperature overnight. The 
reaction mixture was concentrated in vacuo and the resulting 
slurry diluted with ethyl acetate (300 mL).  The organic layer was 
washed with brine (4 x 100 mL), dried (MgSO4) and evaporated 
to give a yellow residue. Upon recrystallization of this crude 
product from hot absolute alcohol, 3 was obtained as pale yellow 
crystals (9.48 g, 30.54 mmol, 83%). Mp 106 – 108 
o
C [Lit.
19
 (aq. 
ethanol) 108 – 109 
o
C]; 
1
H NMR (400 MHz, CDCl3)  0.90 (3H, 
s, CH3), 1.3-2.6 (13H, m), 2.88 (2H, m), 4.51 (2H, m, CH2O), 
5.28 (1H, m, HAHBC=CH), 5.40 (1H, m, HAHBC=CH), 6.04 (1H, 
m, H2C=CH), 6.66 (1H, d, J = 2.7 Hz, C4H), 6.73 (1H, dd, J = 
2.8 and 8.5 Hz, C2H) and 7.19 (1H, d, J = 8.5 Hz, C1H). 
13
C 
NMR (100.4 MHz, CDCl3)  13.84 (q), 21.56 (t), 25.79 (s), 25.88 
(t), 26.54 (t), 29.65 (t), 31.57 (t), 35.84 (t), 38.31 (d), 43.95 (d), 
47.99 (s), 50.37 (d), 68.75 (t), 112.29 (d), 114.78 (d), 117.45 (t), 
126.28 (d), 132.17 (s), 133.50 (d), 137.71 (s) and 156.58 (s). 
 
5.3.5.  2-(2-Propenyl)estrone (4a) and 4-(2-propenyl)estrone 
(5a) 
 These were prepared according to the method as described by 
Patton
19
 via the Claisen rearrangement of 3. A solution of 3 (7.68 
g, 24.74 mmol) in diethylaniline (50 mL) was heated under an 
atmosphere of nitrogen at reflux temperature for 6 h. The cooled 
reaction mixture was diluted with ethyl acetate (300 mL), washed 
with hydrochloric acid (1M, 4 x 100 mL) and then brine (4 x 100 
mL), dried (MgSO4) and evaporated to give a crude product (8.04 
g). A 5.0 g portion of which was fractionated by flash 
chromatography (silica 400 g, ethyl acetate/hexane, 1:2). The 
second fraction that collected gave a creamy residue (4.24 g) 
which was recrystallized from ether/hexane (3:2, 50 mL) to give 
4a as pale yellow crystals (721 mg, 2.32 mmol, 15%). Mp 175 – 
182 
o
C [Lit.
19 
186 - 187 
o
C]; 
1
H NMR (270 MHz, CDCl3)  0.91 
(3H, s, CH3), 1.2-2.6 (13H, m), 2.82 (2H, m, C6-H2), 3.38 (2H, d, 
J = 6.4 Hz, C=CH-CH2), 4.91 (1H, br s, exchanged with D2O, 
OH), 5.16 (2H, m, H2C=CH-), 5.99 (1H, m, H2C=CH-), 6.57 
(1H, s, ArH) and 7.02 (1H, s, ArH). 
 The mother liquor of 4a was evaporated to give a creamy 
residue (3.45 g). A 2.45 g portion of which was recrystallized 
from ether/hexane (2:1, 42 mL) slowly in the refrigerator.  After 
a week, a crop of yellow crystals (461 mg) was obtained which 
contained approximately 75% of 5a and 25% of 4a according to 
1
H NMR. 
 
5.3.6.  2-(2-Propenyl)estrone 3-O-sulfamate (4) 
 This was prepared from 4a (600 mg, 1.93 mmol) in a similar 
manner to the sulfamoylation of 1a.  The crude product that 
obtained was fractionated by flash chromatography (ethyl 
acetate/hexane, 1:4 to 1:1 gradient) to give 4 as fluffy creamy 
residue (540 mg, 72%). Mp 153-155 
o
C; Rf (ethyl acetate/hexane, 
1:1) 0.42, c.f. Rf 0.53 (4a); IR max/cm
-1
 (KBr) 3420, 3340, 3240, 
3080, 2940, 2870, 1720, 1500, 1380, 1180; 
1
H NMR (270 MHz, 
CDCl3)  0.91 (3H, s, CH3), 1.0-2.7 (13H, m), 2.91 (2H, m, C6-
H2), 3.45 (2H, d, J = 6.4 Hz, C=CH-CH2), 4.99 (2H, br s, 
exchanged with D2O, OSO2NH2), 5.08-5.20 (2H, m, H2C=CH-), 
5.97 (1H, m, H2C=CH-), 7.14 (1H, s, ArH) and 7.18 (1H, s, 
ArH); LRMS (FAB
+
) m/z (%) 389.1 [88, M
+
], 147.1(60), 
72.9(100); LRMS (FAB
-
) m/z (%) 542.3 [20, (M+NBA)
-
], 388.1 
[100, (M-H)
-
]; HRMS (FAB
+
) Found: 389.1674. C21H27NO4S 
requires 389.1661. Found: C, 64.9; H, 7.02; N, 3.49. C21H27NO4S 
requires C, 64.75; H, 6.99; N, 3.60%. 
 
5.3.7.  4-(2-Propenyl)estrone 3-O-sulfamate (5) (contained ca. 
25% of 4) 
 This was prepared from 5a (contained ca. 25% of 4a by 
1
H 
NMR, 648 mg, 2.09 mmol) in a similar manner to the 
sulfamoylation of 1a.  The crude product that obtained was 
fractionated by flash chromatography (ethyl acetate/hexane, 1:4 
to 1:1 gradient) and the second fraction that collected 
corresponded to an inseparable mixture of ca. 75% of 5 and 25% 
of 4 as fluffy creamy residue (523 mg). Mp 75-80 
o
C; Rf (ethyl 
acetate/hexane, 2:1) 0.64, c.f. Rf 0.73 (4a and 5a); IR max/cm
-1
 
(KBr) 3480, 3280, 3080, 2940, 2870, 1730, 1480, 1380, 1185; 
1
H 
NMR (400 MHz, CD2Cl2)  0.89 (3H, s, CH3), 1.2-3.0 (15H, m), 
3.48 (2H, m, C=CH-CH2), 5.06 (4H, m, 2H exchanged with D2O, 
H2C=CH- and OSO2NH2), 5.93 (1H, m, H2C=CH-), 7.11 (~ 
0.25H, s, ArH of 2-(2-propenyl) isomer 4), 7.20 (~ 0.25H, ArH 
of 2-(2-propenyl) isomer 4), 7.24 (~ 0.75H, d, J = 8.9 Hz, ArH of 
4-(2-propenyl) isomer 5), 7.28 (~ 0.75H, d, J = 8.9 Hz, ArH of 4-
(2-propenyl) isomer 5); LRMS (FAB
+
) m/z (%) 389.1 [88, M
+
], 
310.2 [31, (M- HNSO2)
+
], 133.1(45), 72.9(64); LRMS (FAB
-
) 
m/z (%) 542.3 [20, (M+NBA)
-
], 388.2 [100, (M-H)
-
]; HRMS 
(FAB
+
) Found: 389.1671. C21H27NO4S requires 389.1661. Found: 
C, 64.8; H, 7.08; N, 3.48. C21H27NO4S requires C, 64.75; H, 6.99; 
N, 3.60%. 
 
5.3.8.  2,4-Di-(2-propenyl)estrone (8a)  
 To a solution of a mixture of 4a and 5a (3.14 g, 10.11 mmol) 
in DMF (20 mL) at ice/water temperature was added cautiously 
sodium hydride (60% in mineral oil, 485 mg, 12.14 mmol).  The 
resulting mixture was heated with 3-bromoprop-1-ene (1.05 mL, 
12.14 mmol) at 80 
o
C for 2 h and then stirred under an 
atmosphere of nitrogen at room temperature overnight. The 
reaction mixture was diluted with ethyl acetate (300 mL) and the 
organic layer separated was washed with brine (300 mL, 4 x 100 
mL), dried (MgSO4) and evaporated to give a brown syrup (3.63 
g). The Claisen rearrangement of this mixture of 2-(2-
propenyl)estrone-3-O-(2-propenyl) ether (6) and 4-(2-
propenyl)estrone-3-O-(2-propenyl) ether (7) was carried out 
according to the method as described by Patton.
19 
The crude 8a 
that obtained was fractionated by flash chromatography (silica 
200 g; ethyl acetate/hexane, 1:3 to 1:2 gradient). The third 
fraction that collected gave a light brown residue which upon 
recrystallization from hot cyclohexane yielded 8a as creamy bar-
shaped crystals (2.64 g, 7.53 mmol, 75%). Mp 119-120 
o
C [Lit.
19
 
(ethanol) 121.5 – 122 
o
C]; Rf (ethyl acetate/hexane, 1:3) 0.43, c.f. 
Rf 0.51 (4a and 4b); 
1
H NMR (270 MHz, CD2Cl2)  0.90 (3H, s, 
CH3), 1.0-3.0 (15H, m), 3.40 (4H, m, 2 x C=CH-CH2), 4.9-5.3 
(5H, m, 1H exchanged with D2O, 2 x H2C=CH- and OH), 6.0 
(2H, m, H2C=CH-) and 6.98 (1H, s, C1H).  
 
5.3.9.  2,4-Di-(2-propenyl)estrone 3-O-sulfamate (8) 
 This was prepared from 8a (1.0 g, 2.85 mmol) in a similar 
manner to the sulfamoylaton of 1a.  The crude product that 
obtained was fractionated by flash chromatography (ethyl 
acetate/hexane, 1:2) to give 8 as fluffy pale yellow residue (722 
mg, 1.68 mmol, 59%). Mp 75-80 
o
C; Rf (ethyl acetate/hexane, 
2:1) 0.64, c.f. Rf 0.72 (8a); 
1
H NMR (270 MHz, CDCl3)  0.91 
(3H, s, CH3), 1.1-3.0 (15H, m), 3.55 (4H, m, 2 x C=CH-CH2), 
4.9-5.3 (6H, m, 2H exchanged with D2O, 2 x H2C=CH- and 
OSO2NH2), 5.97 (2H, m, 2 x H2C=CH-) and 7.15 (1H, s, C1H); 
LRMS (EI, 70 eV) m/z (%) 429.1 [7, M
+
], 350.2 [48, (M-
HN=SO2)
+
] 149.0(40), 43.0[100, (C3H7)
+
]; HRMS (EI) Found: 
429.1999. C24H31NO4S requires 429.1974. Found: C, 66.8; H, 
7.28; N, 3.22. C24H31NO4S requires C, 67.10; H, 7.28; N, 3.26%.  
 
5.3.10. 2-n-Propylestrone 3-O-sulfamate (9) 
 To a solution of 4 (250 mg, 642 mol) in absolute ethanol (50 
mL) was added a suspension of Pd-C (10%, 250 mg) in absolute 
ethanol (2 mL) and the resulting suspension was stirred at room 
temperature overnight under an atmosphere of hydrogen at 50 
psi. After removal of the supported catalyst by filtration and 
evaporation of the filtrate, the crude product obtained was 
fractionated by flash chromatography (ethyl acetate/hexane, 1:4 
to 2:1 gradient) to give 9 as fluffy light yellow residue (220 mg, 
562 mol, 88%). Mp 75-80 oC; Rf (ethyl acetate/hexane, 1:1) 
0.53, c.f. Rf 0.44 (4); IR max/cm
-1
 (KBr) 3380, 3280, 3100, 2960, 
2880, 1730, 1500, 1380, 1200; 
1
H NMR (270 MHz, CDCl3)  
0.91 (3H, s, C18H3), 0.96 (3H, t, J = 7.3 Hz, CH3), 1.2-3.0 (19H, 
m), 4.98 (2H, br s, exchanged with D2O, OSO2NH2), 7.12 (1H, s, 
Ar) and 7.18 (1H, s, Ar); LRMS (FAB
+
) m/z (%) 390.1 [88, (M-
H)
+
], 147.1(55), 73.0(100); LRMS (FAB
-
) m/z (%) 544.2 [17, 
(M+NBA)
-
], 390.1 [100, (M-H)
-
]. Found: C, 64.3; H, 7.61; N, 
3.42. C21H29NO4S requires C, 64.42; H, 7.47; N, 3.58%.  
 
5.3.11. 4-n-Propylestrone 3-O-sulfamate (10) 
 This was prepared from 5 (250 mg, 481 mol, contained ca. 
25% of 4) in a similar manner to the preparation of 9. The crude 
product that obtained was fractionated by flash chromatography 
(ethyl acetate/hexane, 1:4 to 1:1 gradient) and the second fraction 
that isolated gave a mixture of 10 and 9 (ca. 3:1) as creamy 
residue (234 mg). A portion of this residue (145 mg) was 
recrystallized from ethyl acetate/hexane (1:3) to give pure 10 as 
soft white crystals (61 mg, 157 mol, yield: 70% based on the 
amount of 5 present in the crude). Mp 194-198 
o
C; Rf (ethyl 
acetate/hexane, 1:1) 0.42, c.f. Rf 0.40 (5); IR max/cm
-1
 (KBr) 
3400, 3320, 3240, 3000-2860, 1720, 1470, 1390, 1180; 
1
H NMR 
(400 MHz, CD2Cl2)  0.89 (3H, s, C18-H3), 1.00 (3H, t, J = 7.3 
Hz, CH3), 1.2-3.0 (19H, m), 5.11 (2H, br s, exchanged with D2O, 
OSO2NH2) and 7.21 (2H, s, Ar); LRMS (FAB
+
) m/z (%) 391.1 
[100, M
+
]; LRMS (FAB
-
) m/z (%) 544.2 [20, (M+NBA)
-
], 390.1 
[100, (M-H)
-
]. Found: C, 64.1; H, 7.45; N, 3.51. C21H29NO4S 
requires C, 64.42; H, 7.47; N, 3.58%. 
 
5.3.12. 2,4-Di-n-propylestrone 3-O-sulfamate (11) 
 This was prepared from 8 (200 mg, 466 mol) in a similar 
manner to the preparation of 9.  The crude product that obtained 
was fractionated by flash chromatography (ethyl acetate/hexane, 
1:4 to 1:2 gradient) and the second fraction that collected gave 11 
as fluffy creamy residue (190 mg, 438 mol, 94%). Mp 72-82 oC; 
Rf (ethyl acetate/hexane, 1:1) 0.64, c.f. Rf 0.59 (8); IR max/cm
-1
 
(KBr) 3380, 3300, 3100, 2970, 2940, 2880, 1730, 1470, 1380, 
1180; 
1
H NMR (270 MHz, CDCl3)  0.91 (3H, s, C18-H3), 0.96 
(3H, t, J  = 7.3 Hz, CH3), 1.00 (3H, t, J = 7.3 Hz, CH3), 1.3-3.0 
(23H, m), 5.02 (2H, br s, exchanged with D2O, OSO2NH2) and 
7.08 (1H, s, C1H); LRMS (FAB
+
) m/z (%) 433.1 [100, M
+
], 
353.2 [43, (M-H2NSO2)
+
], 255.2(50), 173.1(80); LRMS (FAB
-
) 
m/z (%) 432.2 [100, (M-H)
-
], 353.1 [8, (M-H2NSO2)
-
]; HRMS 
(FAB
+
) Found: 433.2311. C24H35NO4S requires 433.2287. Found: 
C, 66.6; H, 8.37; N, 2.97. C24H35NO4S requires C, 66.48; H, 8.14; 
N, 3.23%.  
 
5.3.13. 2-Fluoroestrone acetate (12a) 
 This was prepared according to the method as described by 
Page et al.
20
 through heating a mixture of estrone (1.50 g, 5.55 
mmol) and N-fluoropyridinium triflate (2.74 g, 11.0 mmol) in 
1,1,2-trichloroethane (24 mL) at reflux temperature under 
nitrogen for 24 h. Mp 83-88
 o
C [Lit.
20
 88-90 
o
C]; 
1
H NMR 
(CDCl3, 270 MHz)  0.91 (3H, s, C18H3), 1.38-1.75 (6H, m), 
1.90-2.45 (6H, m), 2.32 (3H, s, CH3) 2.46-2.57 (1H, m), 2.80-
2.95 (2H, m, C6H), 6.83 (1H, d, J = 8.3 Hz, C4H) and 7.07 (1H, 
d, J = 13.2 Hz, C1H); LRMS (FAB
+
) m/z (%) 331.1 (59, M
+
+1), 
288.1 (100) and 270.1 (22); HRMS (FAB
+
) Found: 331.1705. 
C20H23FO3 (M
+
+1) requires 331.1709.  
 
5.3.14. 2-Fluoroestrone (12b) 
 This was prepared according to the method as described by 
Page et al.
20
 through heating a solution of 12a (185 mg, 560 
mol) in methanol (5 mL) with K2CO3 (387 mg, 5 eq.) under 
reflux for 3 h. The crude residue obtained was recrystallized from 
petroleum ether (bp 60-80 
o
C)/absolute ethanol (2:8) to give 12b 
(121 mg, 75% purity as estimated by 
1
H NMR) as colorless 
crystals (mp 220-227 
o
C). Further purification by semi-
preparative HPLC (Waters Radialpak C18 100 x 25 mm, 
MeOH/H2O (60:40), 20 mL/min, max 254 and 270 nm) gave 12b 
as a white solid (72 mg, 45 %). Mp 220-223
 o
C [Lit.
20
 (petroleum 
ether/absolute ethanol) 220-222 
o
C]; 
1
H NMR (400 MHz, CDCl3) 
 0.78 (3H, s, CH3), 1.37-1.79 (6H, m), 1.91-2.40 (6H, m), 2.46-
2.56 (1H, m), 2.80-2.90 (2H, m, C6H), 5.02 (1H, d, ex. with D2O, 
J = 3.9 Hz, OH), 6.72 (1H, d, J = 9.4 Hz, C4H) and 6.98 (1H, d, J 
= 12.5 Hz, C1H); 
19
F NMR (376 MHz, CDCl3)  -144.50 (1F, t, J 
= 9.2 Hz); LRMS (FAB
+
) m/z (%) 289.0 [100, (M
+
+1)], 149.0 
(33) and 120.0 (35); LRMS (FAB
-
) m/z (%) 287.1.0 [100, (M
-
-
1)], 200.0 (25), 140.0 (25) and 123.0 (43); HRMS (FAB
+
) Found 
288.1520. C18H21FO2 requires 288.1526. HPLC: Waters 
Radialpak C18 8 x 100 mm, MeOH/H2O (60:40), 2 mL/min, max 
270 nm, tR = 11.69 min, purity: 96.9%. 
 
5.3.15. 2-Fluoroestrone-3-O-sulfamate (12)  
 To a stirred solution of 12b (65 mg, 230 mol) in anhydrous 
DMF (7 mL) under an atmosphere of nitrogen was added at room 
temperature 2,6-di-tert-butyl-4-methylpyridine (139 mg, 0.68 
mmol) then a solution of sulfamoyl chloride (0.68M in toluene, 
1.61 mL, 1.13 mmol) via a syringe. After stirring the reaction 
mixture at room temperature for 18 h, ethyl acetate (60 mL) was 
added and the organic layer separated was washed with brine (3 x 
50 mL), dried (MgSO4), filtered and evaporated. The crude 
product obtained was purified by flash chromatography 
(chloroform/acetone, 8:1) to afford 12 as a white solid, (47 mg, 
57%). Mp 189-193 
o
C; Rf (chloroform/acetone, 8:1) 0.32; 
1
H 
NMR (400 MHz, CDCl3)  0.91 (3H, s, CH3), 1.36-1.70 (6H, m), 
1.92-2.36 (6H, m), 2.46-2.57 (1H, m), 2.80-2.95 (2H, m, C6H), 
5.03 (2H, br s, ex. with D2O, -OSO2NH2), 7.11 (1H, d, J = 9.7 
Hz, C4H) and 7.13 (1H, d, J = 15.5 Hz, C1H); 
19
F NMR (CDCl3, 
376 MHz)  -113.24 (1F, dd, J = 15.5 Hz and  J = 9.7 Hz); 
LRMS (FAB
+
) m/z (%) 367.0 (100, M
+
), 350.0 (30), 288.1 (49), 
258.0 (32), 243.1 (38), 178 (34), 133.0 (30) and 97.0 (35); LRMS 
(FAB
-
) m/z (%) 366.0 [100, (M-H)
-
] and 77.9 (21); HRMS 
(FAB
+
) Found: 367.1267. C18H22NO4S requires 367.1254. HPLC: 
Waters “Symmetry” C18 (packing: 3.5 m, 4.6 x 150 mm); 
mobile phase MeCN/H2O (90/10) isocratic; flow rate, 1 mL/min; 
tR = 2.19 min; purity: 95%. 
 
5.3.16. Estrone acetate (13) 
 This was prepared from estrone according to the method as 
described by Page et al.
20
  
 
5.3.17. 2-Chloroestrone acetate (15a) 
 This was prepared according to the method as described by 
Page et al.
20
 To a solution of 13 (500 mg, 1.60 mmol) in 
trifluoroacetic acid (TFA, 20 mL) was added thallic 
trifluoroacetate (1.74 g, 3.21 mmol) was and the resulting 
mixture was stirred at 0 
o
C under nitrogen for 24 h. Upon 
removal of TFA under reduced pressure at < 40 
o
C, the 
crystalline estrone-thallium (III) complex (14) that obtained was 
washed twice with 1,2-dichloroethane. 1,4-Dioxane (10 mL) and 
copper chloride (475 mg, 4.80 mmol) were then added to this 
washed complex and the resulting mixture was heated under 
reflux for 3 h. Upon cooling and evaporation of solvent, the 
residue that obtained was treated with water (30 mL) and the 
organic components were extracted into dichloromethane (3 x 50 
mL). The combined organic extracts were washed with water, 
dried (MgSO4), filtered and evaporated. The crude product that 
obtained was fractionated by flash chromatography (ethyl 
acetate/hexane, 1:4) and the pale yellow solid that obtained (526 
mg) was further purified by recrystallization from methanol to 
give 15a as white crystals (436 mg, 78%). Mp 195-197 
o
C; Rf 
(chloroform/acetone, 8:1) 0.78; IR max/cm
-1
 (KBr) 1770, 1730 
(C=O); 
1
H NMR (400 MHz, CDCl3)  0.90 (3H, s, C18H3), 1.38-
2.29 (12H, m), 2.33 (3H, s, CH3CO), 2.5 (1H, m), 2.87 (2H, m, 
C6H), 6.85 (1H, s, C4H) and 7.34 (1H, s, C1H). 
 
5.3.18. 2-Chloroestrone (15b)  
 This was prepared according to the method as described by 
Page et al.
20
 A mixture of 15a (400 mg, 1.15 mmol), K2CO3 
(800mg, 5.80 mmol) in MeOH (20 mL) was heated under reflux 
for 3 h. Upon cooling and evaporation of the solvent, water (20 
mL) was added to the residue that obtained and the crude product 
was extracted into dichloromethane (3 x 20 mL). The combined 
organic extracts were washed with water, dried (MgSO4), filtered 
and evaporated to give a yellow crude product which was 
purified by recrystallization from methanol to give 15b as white 
crystals (320 mg, 90%). Mp 221-223 
o
C [Lit.
20
 223-225 
o
C]; Rf 
(chloroform/acetone, 8:1) 0.70; IR max/cm
-1
 (KBr) 3400 (OH), 
1730 (C=O); 
1
H NMR (270 MHz, CDCl3)  0.91 (3H, s, CH3), 
1.4-2.54 (13H, m), 2.84 (2H, m, C6H), 5.27 (1H, s, ex, with D2O, 
OH), 6.71 (1H, s, C4H) and 7.31 (1H, s, C1H). 
 
5.3.19. 2-Chloroestrone 3-O-sulfamate (15)  
 This was prepared from 15b (200 mg, 655 mol) in a similar 
manner to the sulfamoylation of 1a. The crude product that 
obtained was fractionated by flash chromatography 
(chloroform/acetone, 8:1) to give a beige residue (190 mg) which 
was further purified by recrystallization from acetone/hexane 
(1:2) to give 15 as white crystals (170 mg, 68%). Mp > 163 
o
C 
(dec.); Rfs (chloroform/acetone, 8:1 and 4:1) 0.63 and 0.74 
respectively; IR max/cm
-1
 (KBr) 3500, 3200 (NH2), 1720 (C=O), 
1390 (SO2); 
1
H NMR (400 MHz, CDCl3/DMSO-d6: 10:1)  0.93 
(3H, s, CH3), 1.4-2.51 (13H, m), 2.86 (2H, m, C6H), 7.01 (2H, br 
s, ex. with D2O, OSO2NH2), 7.25 (1H, s, C4H) and 7.35 (1H, s, 
C1H). LRMS (FAB
+
) m/z (%) 537.2 (5), 383.2 (17), 206.2 (100), 
97.1 (22); LRMS (FAB
-
) m/z (%) 536.2 (45), 383.2 (100), 250.0 
(52), 96.9 (49), 77.9 (34); HRMS (FAB
+
) Found: 383.0956. 
C18H22ClNO4S requires 383.0958. HPLC: Waters “Symmetry” 
C18 (packing: 3.5 m, 4.6 x 150 mm); mobile phase MeCN/H2O 
(96/4) isocratic; flow rate, 1 mL/min; tR = 2.01 min; purity: 98%.  
 
5.3.20. 2-Bromoestrone acetate (16a) 
 This was prepared from 13 (2.0 g, 6.40 mmol) in the same 
manner as the preparation of 15a except that copper bromide 
(8.58 g, 38.41 mmol) was used. The crude product obtained was 
fractionated by flash chromatography (ethyl acetate/hexane, 1:4) 
and the pale white solid that isolated (2.05 g) was further purified 
by recrystallization from methanol to give 16a as colorless 
crystals (1.79 g, 4.58 mmol, 72%). Mp 229-231 
o
C; Rfs 
(chloroform/acetone, 8:1 and ethyl acetate/hexane, 4:1) 0.89 and 
0.62 respectively; IR max/cm
-1
 (KBr) 1770, 1730 (C=O) cm
-1
; 
1
H 
NMR (400 MHz, CDCl3)  0.91 (3H, s, C18H3), 1.25-2.3 (12H, 
m), 2.34 (3H, s, CH3CO), 2.5 (1H, m), 2.86 (2H, t, J = 4.6 Hz, 
C6H), 6.85 (1H, s, C4H) and 7.49 (1H, s, C1H); LRMS m/z 
(FAB
+
) 545.2 [90, (M+H+NBA)
+
], 391.2 [100, (M)
+
], 348.1 [90, 
(M-CH3CO)
+
] and 330.1 (10); HRMS (FAB
+
) Found: 391.0856. 
C20H24BrO3 requires 391.0909. Found: C, 61.2; H, 5.89. 
C20H23BrO3 requires C, 61.39; H, 5.92%.  
 
5.3.21. 2-Bromoestrone (16b) 
 This was prepared from 16a (1.5 g, 3.83 mmol) in the same 
manner as the preparation of its chloro analogue 15b. The pale 
yellow crude product (1.3 g) obtained was purified by 
recrystallization from ethyl acetate/petroleum ether 60-80 
o
C 
(3:2) to give 16b as pale yellow crystals (1.23 g, 3.52 mmol, 
92%). Mp 190-193 
o
C [Lit.
20
 194-195 
o
C]; Rfs 
(chloroform/acetone, 8:1 and 4:1) 0.51 and 0.64 respectively; IR 
max/cm
-1
 (KBr) 1710 (C=O); 
1
H NMR (400 MHz, CDCl3)  0.87 
(3H, s, C18H3), 1.4-2.52 (13H, m), 2.84 (2H, m, C6H), 5.32 (1H, 
br s, ex. with D2O, OH), 6.73 (1H, s, C4H) and 7.52 (1H, s, 
C1H); 
13
C NMR (100.4 MHz, CDCl3)  13.81 (q, C18), 21.56 (t), 
25.89 (t), 26.26 (t), 29.9 (t), 31.54 (t), 31.91 (t), 38.04 (d), 43.6 
(d), 47.93 (s, C13), 50.38 (d), 114.94 (d, C4), 135.04 (d, C-1), 
128.84 (s), 130.92 (s), 139.02 (s), 152.7 (s, C3) and 220 (s, 
C=O); LRMS (FAB
+
) m/z (%) 502.1 [20, (M+NBA)
+
], 349.1 
[100, (M)
+
] and 271.0 (20); LRMS (FAB
-
) m/z (%) 502.2 [40, 
(M+NBA)
-
] and 348.1 [100, (M-H)
-
]; HRMS (FAB
+
) Found: 
348.0753. C18H21BrO2 requires 348.0725.  
 
5.3.22. 2-Bromoestrone 3-O-sulfamate (16) 
 This was prepared from 16b (500 mg, 1.43 mmol) in a similar 
manner to the sulfamoylation of 1a. The crude product (620 mg) 
obtained was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The beige residue obtained (510 mg) 
was further purified by recrystallization from acetone/hexane 
(1:2) to give 16 as beige crystals (405 mg, 66%). Mp > 155 
o
C 
(dec.); Rfs (chloroform/acetone, 8:1 and 4:1) 0.43 and 0.61 
respectively; IR max/cm
-1
 (KBr) 3500, 3300 (NH2), 1730 (C=O), 
1390 (SO2); 
1
H NMR (400 MHz, acetone-d6)  0.92 (3H, s, CH3), 
1.41-2.49 (13H, m), 2.86 (2H, m, C6H), 7.27 (1H, s, C4H), 7.32 
(2H, br s, ex. with D2O, OSO2NH2) and 7.55 (1H, s, C1H); 
LRMS (FAB
+
) m/z (%) 428.1 [100, (M)
+
] and 349.2 [40, (M+H-
SO2NH2)
+
]; LRMS (FAB
-
) m/z (%) 580.2 [M-H+NBA], 428.1 
[100, (M)
-
] and 349.1 [30, (M+H-SO2NH2)
-
]; HRMS (FAB
+
) 
Found: 428.0430. C18H23BrNO4S requires 428.0531. HPLC: 
Waters “Symmetry” C18 (packing: 3.5 m, 4.6 x 150 mm); 
mobile phase MeCN/H2O (90/10) isocratic; flow rate, 1 mL/min; 
tR = 2.19 min; purity: 98%.  
 
5.3.23. 2-Iodoestrone acetate (17a) 
 This was prepared from 13 (5.0 g, 16.01 mmol) in the same 
manner as the preparation of 15a except that copper iodide (18.29 
g, 96.03 mmol) was used. The crude product obtained was 
purified by flash chromatography with ethyl acetate/hexane (1:4) 
and the yellow solid obtained (6.25 g) was further purified by 
recrystallization from methanol to give 17a as pale yellow 
crystals (5.89 g, 84%). Mp 170-172 
o
C (crystals turned brown at 
> 145 
o
C); Rf (chloroform/acetone, 8:1) 0.8; IR max/cm
-1
 (KBr) 
1770, 1730 (C=O); 
1
H NMR (400 MHz, CDCl3)  0.92 (3H, s, 
C18H3), 1.4-2.31 (12H, m), 2.34 (3H, s, CH3CO), 2.5 (1H, m), 
2.87 (2H, t, J = 4.27 Hz, C6H), 6.82 (1H, s, C4H) and 7.69 (1H, 
s, C1H); LRMS (FAB
+
) m/z (%) 592.1 [20, (M+H+NBA)
+
], 
439.1 [80, (M+H)
+
], 396.1 [100, (M+H-CH3CO)
+
] and 270.2 
(40); HRMS (FAB
+
) Found: 439.0767. C20H24IO3 requires 
439.0770. 
 
5.3.24. 2-Iodoestrone (17b) 
 This was prepared from 17a (4.0 g, 9.13 mmol) in the same 
manner as the preparation of its chloro analogue 15b. The yellow 
crude product obtained was recrystallized from methanol to give 
17b as pale yellow crystals (3.29 g, 91%). Mp 207-209 
o
C 
(crystals turned brown at >169 
o
C) [Lit.
20
 167-168 
o
C]; Rf  
(chloroform/acetone, 8:1) 0.75; IR max/cm
-1
 (KBr) 3400 (OH), 
1730 (C=O) cm
-1
; 
1
H NMR (270 MHz, CDCl3)  0.91 (3H, s, 
CH3), 1.4-2.56 (13H, m), 2.83 (2H, m, C6H), 5.24 (1H, s, ex. 
with D2O, OH), 6.74 (1H, s, C4H) and 7.52 (1H, s, C1H); 
13
C 
NMR (100.4 MHz, CDCl3)  13.82 (q, C-18), 21.57 (t), 25.89 (t), 
26.26 (t), 29.98 (t), 31.57 (t), 31.81 (t), 39.0 (d), 43.9 (d), 48.3 (s, 
C13), 50.38 (d), 116.54 (d, C4), 138.14 (d, C1), 129.64 (s), 
131.92 (s), 138.02 (s), 153.6 (s, C3) and 220 (s, C17, C=O); 
LRMS (FAB
+
) m/z (%) 550.1 [20, (M+H+NBA)
+
], 396.1 [100, 
(M)
+
] and 271.2 (40); LRMS (FAB
-
) m/z (%) 549.2 [20, 
(M+NBA)
-
] and 395.1 [100, (M-H)
-
]; HRMS (FAB
+
) Found: 
397.0651. C18H22IO2 requires 397.0665. 
 
5.3.25. 2-Iodoestrone 3-O-sulfamate (17) 
 This was prepared from 17b (500 mg, 1.26 mmol) in a similar 
manner to the sulfamoylation of 1a. The crude product obtained 
was fractionated by flash chromatography (chloroform/acetone, 
8:1) and the beige residue that collected (450 mg) was further 
purified by recrystallization from acetone/hexane (1:2) to give 17 
as beige crystals (342 mg, 57%). Mp > 145 
o
C (dec.); Rfs 
(chloroform/acetone, 8:1 and 4:1) 0.61 and 0.73 respectively; IR 
max/cm
-1 
(KBr) 3500, 3200 (NH2), 1720 (C=O), 1390 (SO2); 
1
H 
NMR (400 MHz, acetone-d6)  0.92 (3H, s, CH3), 1.4-2.53 (13H, 
m), 2.83 (2H, m, C6H), 7.25 (1H, s, C4H), 7.32 (2H, br s, ex. 
with D2O, OSO2NH2) and 7.76 (1H, s, C1H); LRMS (FAB
+
) m/z 
(%) 629.1 [40, (M+H+NBA)
+
], 476.1 [100, (M+H)
+
] and 396.1 
[40, (M+H-SO2NH2)
+
]; LRMS (FAB
-
) m/z (%) 628.1 [35, 
(M+NBA)
-
], 474.1 [100, (M-H)
-
] and 395.1 [20, (M-SO2NH2)
-
]; 
HRMS (FAB
+
) Found: 476.0387. C18H23INO4S requires 
476.0393. Found: C, 45.8; H; 4.74; N, 2.85. C18H22INO4S 
requires C, 45.48; H, 4.66; N, 2.95%. 
 
5.3.26. 2-Cyanoestrone (18b) 
 2-Cyanoestrone acetate (18a) was prepared from 13 (500 mg, 
1.60 mmol) in the same manner as the preparation of 15a except 
that the estrone-thallium (III) complex was heated with copper 
cyanide in pyridine instead. Without the isolation of product, 
crude 18a obtained was directly deacetylated in the same manner 
as the preparation of its chloro analogue 15b. Upon fractionation 
of crude 18b by flash chromatography (ethyl acetate/hexane, 
1:4), the pale yellow solid obtained (286 mg) was further purified 
by recrystallization from methanol to give 18b as white crystals 
(260 mg, 80%). Mp 266-268 
o
C [Lit.
20
 265-266 
o
C]; Rf 
(chloroform/acetone, 8:1) 0.74; IR max/cm
-1
 (KBr) 1770, 1730 
(C=O) cm
-1
, 
1
H NMR (400 MHz, CDCl3)  0.92 (3H, s, CH3), 
1.39-2.56 (13H, m), 2.86 (2H, m, C6CH2), 5.97 (1H, br s, ex. 
with D2O, C3OH), 6.71 (1H, s, C4H) and 7.52 (1H, s, C1H). 
 
5.3.27. 2-Cyanoestrone 3-O-sulfamate (18) 
 This was prepared from 18b (200 mg, 677 mol) in a similar 
manner to the sulfamoylation of 1a. The crude product obtained 
was fractionated by flash chromatography (chloroform/acetone, 
8:1) and the pale yellow residue that collected (217 mg) was 
further purified by recrystallization from acetone/hexane (1:2) to 
give 12 as beige crystals (181 mg, 70%); Mp > 205 
o
C (dec.); Rfs 
(chloroform/acetone, 8:1 and 4:1) 0.60 and 0.72 respectively; IR 
max/cm
-1
 (KBr) 3500, 3200 (NH2), 1720 (C=O), 1390 (SO2); 
1
H 
NMR (400 MHz, CDCl3/DMSO-d6; 5:1)  0.91 (3H, s, CH3), 1.4-
2.49 (13H, m), 2.99 (2H, m, C6H), 7.33 (1H, s, C4H), 7.57 (1H, 
s, C1H) and 8.0 (2H, br s, ex. with D2O, OSO2NH2); LRMS 
(FAB
+
) m/z (%) 528.2 [24, (M+H+NBA)
+
], 375,1 [65, (M+H)
+
], 
206.2 (100); LRMS (FAB
-
) m/z (%) 527.2 [24, (M+NBA)
-
], 
373,2 [65, (M-H)
-
], 294.2 [43, (M-H2NSO2)
-
]; HRMS (FAB
+
) 
Found: 375.1375. C19H23N2O4S requires 375.1379. HPLC: 
Waters “Symmetry” C18 (packing: 3.5 m, 4.6 x 150 mm); 
mobile phase MeCN/H2O (70/30) isocratic; flow rate, 1 mL/min; 
tR = 1.12 min; purity: 94%.  
 
5.3.28. 4-Bromoestrone (19a) 
 To 300 mL of glacial acetic acid was added estrone (1.0 g, 
3.70 mmol) and the suspension was gently heated with stirring 
until it became a solution. Upon cooling to ice-water temperature, 
powdered iron (10-15 mg) was added to the stirred solution, 
followed by a dropwise addition of a 5% v/v solution of bromine 
in glacial acetic acid until the reaction mixture no longer 
decolorized the added bromine. After stirring for an additional 5 
min, the reaction mixture was poured into ice and water. The 
precipitate that formed was collected by filtration, washed with 
water and recrystallized from 98% ethanol to give 19a as white 
powder (300 mg, 858 mol, 23%). Mp  260-263 oC (Lit.21 264-
265 
o
C); Rf (chloroform/acetone, 4:1) 0.76; 
1
H NMR (270 MHz, 
CDCl3)  0.90 (3H, s, C18H3), 1.30-3.06 (15H, m), 5.55 (1H, s, 
ex. with D2O, OH), 6.88 (1H, d, J = 8.6 Hz, C2H) and 7.19 (1H, 
d, J = 8.6 Hz, C1H); LRMS (FAB
+
) m/z (%) 349.1 [84, (M+1)
+
], 
348.1 (100); LRMS (FAB
-
) m/z (%) 502.1 [64, (M-H+NBA)
-
], 
500.1 (55), 349.1 [100, (M-H)
-
], 347.1 (88). HRMS (FAB
+
) 
Found: 348.0716. C18H21BrO2 requires 348.0725. 
 
5.3.29. 4-Bromoestrone sulfamate (19) 
 This was prepared from 19a (286 mg, 816 mol) in a similar 
manner to the sulfamoylation of 1a. The crude product obtained 
was fractionated by flash chromatography (acetone/hexane, 1:4) 
The residue that collected was further purified by 
recrystallization from ethyl acetate/hexane to give 19 as white 
solid (90 mg, 26%). Mp 200-201 
o
C; Rf (chloroform/acetone, 4:1) 
0.47, c.f. Rf 0.76 (19a); IR max/cm
-1
 (KBr) 3361, 3228 (NH2), 
1719 (C=O), 1390 (SO2); 
1
H NMR (400 MHz, CDCl3)  0.91 
(3H, s, CH3), 1.36-1.72 (6H, m), 1.92-2.22 (4H, m), 2.25-2.42 
(2H, m), 2.47-2.58 (1H, m), 2.71-2.84 (1H, m), 3.00-3.10 (1H, 
m), 4.99 (2H, br s, ex. with D2O, OSO2NH2) and 7.29 (2H, d, J = 
7.3 Hz, C1H and C2H); LRMS (FAB
+
) m/z (%) 428.1 [100, 
(M+H)
+
], 349.1 [27, (M-SO2NH2)
+
] 348.1 (30),  476.1 [100, 
(M+H)
+
] and 396.1 [40, (M+H-SO2NH2)
+
]; LRMS (FAB
-
) m/z 
(%) 580.1 [45, (M-H+NBA)
-
], 428.1 [98, (M)
-
], 349.1 (10), 347.1 
[8, (M+H-SO2NH2)
-
], 77.9 (50); HRMS (FAB
+
) Found: 
428.0460. C18H23BrNO4S requires 428.0531. Found: C, 50.6; H; 
5.21; N, 3.18. C18H22BrNO4S requires C, 50.47; H, 5.18; N, 
3.27%.  
 
5.3.30. 3-Hydroxy-1,3,5(10)-estratriene (20a) 
 This was prepared by heating a mixture of estrone (10.0 g, 
36.98 mmol), hydrazine monohydrate (15 mL, mmol), potassium 
hydroxide (15 g, mmol) in ethanol (5 mL) and diethylene glycol 
(120 ml) under the conditions for a Wolff-Kishner reduction of 
steroid ketones. The crude product obtained was purified by flash 
chromatography (ethyl acetate/hexane, 1:4) to give 20a (7.0 g, 
65%). Mp 132-135 
o
C [Lit.
22
 (aq. ethanol) 134 – 134.5 
o
C]; IR 
max/cm
-1
 (KBr) 3371 (OH), 2926 (ArH); 
1
H NMR (400 MHz, 
CDCl3)   0.74 (3H, s), 1.08-1.94 (13H, m), 2.14-2.30 (2H, m), 
2.74-2.90 (2H, m, C6H), 4.47 (1H, s, ex. with D2O, OH), 6.56 
(1H, d, J = 2.7 Hz, C4H), 6.62 (1H, dd, J = 2.7 and 8.6 Hz, C2H) 
and 7.17 (1H, d, J = 8.6 Hz, C1H); LRMS (FAB
+
) m/z (%) 256.1 
(100, M
+
), 159.1 (17), 145.0 (8) and 133.0 (11); LRMS (FAB
-
) 
m/z (%) 408.2 [51, (M-H+NBA)
-
], 255.2 [100, (M-H)
-
], 195.1 
(21) and 139.0 (9); HRMS (FAB
+
) Found: 256.1826. C18H24O 
requires 256.1827. 
 
5.3.31. 1,3,5(10)-Estratriene 3-O-sulfamate (20) 
 This was prepared from 20a (1.0 g, 3.90 mmol) in a similar 
manner to the sulfamoylation of 1a. The crude product obtained 
was fractionated by flash chromatography (ethyl acetate/hexane, 
1:3) and the second fraction that collected (911 mg, 69%) was 
recrystallized from chloroform/hexane (6:7) to give a crop of 20 
as white crystals (280 mg); Mp 124-125 
o
C; Rf (ethyl 
acetate/hexane, 1:2) 0.40, c.f. Rf 0.50 (20a); IR max/cm
-1
 (KBr) 
3410 and 3100 (NH2), 3000-2800, 1380, 1360; 
1
H NMR (270 
MHz, CDCl3)  0.74 (3H, s, CH3), 1.0-3.0 (17H, m), 4.91 (2H, s, 
ex. with D2O, OSO2NH2), 7.04 (1H, d, J = 2.3 Hz, C4H), 7.07 
(1H, dd, J = 2.3 and 8.4 Hz, C2H) and 7.32 (1H, d, J = 8.6 Hz, 
C1H); LRMS (CI) m/z (%) 353.1 [100, (M+NH4)
+
], 257 (11), 256 
(19), 255 (11); HRMS (NH4
+
) Found: 353.1897. C18H29N2O3S 
requires 353.1899. Found: C, 64.3; H, 7.55; N, 4.16. C18H25NO3S 
requires C, 64.45; H, 7.51; N, 4.18%. 
 
 
 
5.3.32.  2-Aminoestrone (21a) 
 To a solution of 1a (1.0 g, 3.17 mmol) in dichloromethane 
(50 mL) was added a suspension of Pd-C (10%, 200 mg) in 
dichloromethane (3 mL). The resulting suspension was stirred at 
room temperature under an atmosphere of hydrogen (balloon) for 
20 h at which time the reduction was complete according to TLC. 
After removal of the supported catalyst by filtration and 
evaporation of filtrate, the crude product that obtained (940 mg) 
[Rf (chloroform/acetone, 4:1) 0.31, c.f. Rf 0.76 (1a)] was used for 
the next reaction without further purification. 
 
5.3.33.  2-Tosylamidoestrone (21b) 
 To a stirred suspension of the freshly prepared crude 21a 
(900 mg, 3.15 mmol) in anhydrous dichloromethane (30 mL) at 
ice/water temperature was added anhydrous pyridine (0.5 mL) 
followed by tosyl chloride (605 mg, 3.17 mmol).  After stirring at 
room temperature for 3 h, the reaction mixture was filtered and 
the filtrate thus obtained was diluted with ethyl acetate (50 mL).  
The organic layer was washed with hydrochloric acid (1M, 2 x 
50 mL) followed by brine (4 x 50 mL), dried (MgSO4), filtered 
and evaporated to give a yellow residue (1.23 g). This was 
recrystallized from ethyl acetate/hexane (4:3) to give a crop of 
slightly impure 21b as fine bright yellow crystals (390 mg).  The 
yellow residue (720 mg) that obtained from the evaporation of 
the mother liquor was fractionated by flash chromatography 
(ethyl acetate/hexane, 1:2 to 4:1 gradient).  The third fraction that 
obtained gave a white residue (568 mg) which was recrystallized 
from ethyl acetate/hexane (2:3) to give 21b as soft creamy 
crystals (365 mg, 830 mol, overall yield ca. 45%). Mp 217-220 
o
C; Rf (ethyl acetate/hexane, 2:1) 0.45, c.f. Rf 0.58 (1a); IR 
max/cm
-1 
(KBr) 3380, 3240, 3000-2800, 1710, 1340, 1160; 
1
H 
NMR (400 MHz, DMSO-d6)  0.80 (3H, s, C18H3), 1.1-2.5 
(16H, m), 2.65 (2H, m, C6H2), 6.42 (1H, s, C4-H), 6.87 (1H, s, 
C1H), 7.31 (2H, AA’BB’, Tosyl), 7.61 (2H, AA’BB’, Tosyl), 
9.01 (1H, s, ex. with D2O, NH or OH) and 9.18 (1H, s, ex. with 
D2O, NH or OH); LRMS (FAB
+
) m/z (%) 439.1 (74, M
+
), 284.1 
[100, (M-Tosyl)
+
]; LRMS (FAB
-
) m/z (%) 592.2 [11, (M+NBA)
-
], 438.1 [100, (M-H)
-
]; HRMS (FAB
+
) Found: 439.1817. 
C25H29NO4S requires 439.1817. Found: C, 68.1; H, 6.82; N, 3.13. 
C25H29NO4S requires C, 68.31; H, 6.65; N, 3.19%. 
 
5.3.34.  Estra-1,3,5(10)-trien-17-oxo[3,2d]-1,2,3-
oxathiazole-3-tosyl-2,2-dioxide (21c) 
 Sulfuryl chloride (1.40 mL of a 0.5 M solution in 
dichloromethane, 700 mol) was added dropwise over a 5 min 
period to a stirred mixture of 21b (280 mg, 637 mol) and 
triethylamine (0.27 mL, 1.911 mmol) in dichloromethane (10 
mL) at –78 
o
C under an atmosphere of nitrogen. After an 
additional 15 min, the reaction mixture was allowed to warm to 
room temperature, concentrated and the yellow residue that 
obtained was dissolved in ethyl acetate (50 mL). The organic 
layer was washed with hydrochloric acid (1M, 50 mL) followed 
by brine (4 x 50 mL), dried (MgSO4), filtered and evaporated to 
give a yellow residue (390 mg) which was fractionated by flash 
chromatography (chloroform/acetone, 16:1). The first fraction 
that isolated upon evaporation gave the product (192 mg, 383 
mol, 60%) which was recrystallized from ethyl acetate/hexane 
to give 21c as white crystals (90 mg). Mp 245-247 
o
C (dec.); IR 
max/cm
-1
 (KBr) 3000-2850, 1745, 1400, 1390, 1220; 
1
H NMR 
(400 MHz, CDCl3)  0.94 (3H, s, C18H3), 1.40-1.75 (6H, m), 
2.0-2.6 (10H, m), 2.87 (2H, m, C6H2), 6.79 (1H, s, C4H), 7.31 
(2H, AA’BB’, Tosyl), 7.57 (1H, s, C1H) and 7.82 (2H, AA’BB’, 
Tosyl); LRMS (FAB
+
) m/z (%) 655.0 [25, (M+H+NBA)
+
], 501.0 
(100, M
+
), 420.2 (45), 346.0 [70, (M-Tosyl)
+
]; LRMS (FAB
-
) m/z 
(%) 346.2 [100, (M-Tosyl)
-
]; HRMS (FAB
+
) Found: 501.1299. 
C25H27NO6S2 requires 501.1280. Found: C, 59.6; H, 5.46; N, 
2.80. C25H27NO6S2 requires C, 59.86; H, 5.43; N, 2.79%.  
 
5.3.35.  Estra-1,3,5(10)-trien-17-oxo[3,2d]-1,2,3-
oxathiazole-2,2-dioxide (21) 
 To a solution of 21c (148 mg, 295 mol) in acetonitrile (25 
mL) was added a solution of potassium fluoride (171 mg, 2.95 
mmol) in water (4 mL). The resulting white suspension/emulsion 
was refluxed for 3 h, cooled and evaporated.  The white residue 
that obtained was dissolved in ethyl acetate (50 mL) and the 
organic layer washed with hydrochloric acid (1M, 50 mL) 
followed by brine (4 x 50 mL). After drying (MgSO4) and 
filtration, the filtrate on evaporation gave a light purple residue 
(141 mg) which was recrystallized from ethyl acetate/hexane 
(1:3, 8 mL) to give 21 as light purple powder (68 mg, 196 mol, 
66%). Mp 130-137 
o
C; IR max/cm
-1
 (KBr) 3700-2500, 2920, 
2860, 1720, 1490, 1370, 1190; 
1
H NMR (400 MHz, CDCl3)  
0.92 (3H, s, C18H3), 1.40-1.70 (6H, m), 1.90-2.40 (6H, m), 2.52 
(1H, dd, J 8.8 and ~ 19 Hz), 2.90 (2H, m, C6H2), 6.73 (1H, s, ex. 
with D2O, NH), 6.86 (1H, s, Ar) and 6.97 (1H, s, Ar); LRMS 
(FAB
+
) m/z (%) 500.9 [7, (M+H+NBA)
+
], 346.9 (100, M
+
); 
LRMS (FAB
-
) m/z (%) 693.4[10, (2M-H)
-
], 346.2 [100, (M-H)
-
]; 
HRMS (FAB
+
) Found: 347.1196. C18H21NO4S requires 347.1191. 
HPLC: Waters “Symmetry” C18 (packing: 3.5 m, 4.6 x 100 
mm); mobile phase MeCN/H2O (96/4), gradient elution: 50:50 
MeCN/H2O to 95:5 MeCN/H2O over 5 min; flow rate, 1 mL/min; 
tR = 2.01 min; purity: 98%.   
 
5.3.36.  Estra-1,3,5(10)-trien-17-oxo[3,2d]-1,2,3-
oxathiazole-3-methyl-2,2-dioxide (22) 
 To a solution of 21 (32 mg,  92 mol) in anhydrous DMF (5 
mL) at room temperature was added sodium hydride (60% 
dispersion in mineral oil, 4 mg, 100 mol). After 10 min, the 
resulting yellow mixture was heated in the presence of methyl 
iodide (0.2 mL, 3.21 mmol) at 90 
o
C for 3 h. Upon cooling and 
diluting with ethyl acetate (20 mL), the organic layer that 
separated was washed with brine (30 mL, 4 x 10 mL), dried 
(MgSO4), filtered and evaporated to give a light brown residue 
(37 mg) which was recrystallized from ethyl acetate/hexane (3:4 , 
7 mL) to give 22 as light yellow/brown crystals (12 mg, 33 mol, 
36%). Mp turned brown at ca. 230 
o
C and melted at > 250 
o
C to 
form a dark brown syrup; Rf (chloroform/acetone, 1:1) 0.80, c.f. 
Rf 0.51 (21); 
1
H NMR (400 MHz, CDCl3)  0.93 (3H, s, C18H3), 
1.40-2.60 (~ 13H), 2.88 (2H, m, C6H2), 3.26 (3H, s, NCH3), 6.73 
(1H, s, Ar) and 6.84 (1H, s, Ar); LRMS (FAB
+
) m/z (%) 361.2 
(100, M
+
), 330.2 (8), 298.3 (17), 173.2 (17), 97.1 (15); LRMS 
(FAB
-
) m/z (%) no peaks were observed; HRMS (FAB
+
) Found: 
361.1359. C19H23NO4S requires 361.1348. HPLC: Waters 
“Symmetry” C18 (packing: 3.5 m, 4.6 x 150 mm); mobile phase 
MeCN/H2O (96/4) isocratic; flow rate, 1 mL/min; tR = 2.39 min; 
purity: >99%.  
 
5.3.37.  4-Aminoestrone (23a) 
 To a solution of 2a (1.49 g, 4.73 mmol) in tetrahydrofuran 
(THF, 80 mL) was added a suspension of Pd-C (10%, 300 mg) in 
THF (2 mL) and the resulting suspension was stirred at room 
temperature under an atmosphere of hydrogen (balloon) for 20 h.  
After removal of the supported catalyst by filtration and 
evaporation of filtrate, the crude product that obtained (1.42 g) 
[Rf chloroform/acetone, 4:1) 0.53, c.f. Rf 0.68 (2a)] was used for 
the next reaction without further purification. 
 
 
 
5.3.38.  4-Tosylamidoestrone (23b) 
 To a stirred suspension of the freshly prepared crude 23a 
(500 mg, 1.75 mmol) in anhydrous dichloromethane (15 mL) at 
ice/water temperature was added anhydrous pyridine (0.28 mL) 
followed by tosyl chloride (334 mg, 1.75 mmol).  After stirring at 
room temperature for 3 h, the reaction mixture was diluted with 
ethyl acetate (100 mL).  The organic layer was washed with 
hydrochloric acid (1M, 50 mL) followed by brine (4 x 50 mL), 
dried (MgSO4), filtered and evaporated to give a yellow residue 
(790 mg) which was fractionated by flash chromatography (ethyl 
acetate/hexane, 1:1 to 2:1 gradient). The major fractions that 
isolated gave a light yellow residue (670 mg) and this was 
recrystallized from acetone/diethyl ether (1:25, 52 mL) in the 
refrigerator to give 23b as light yellow crystals (185 mg, 421 
mol, 24%), mp 206-209 oC; TLC (chloroform/acetone, 4:1) Rf 
0.64, c.f. Rf 0.49 (23a); IR max/cm
-1
 (KBr) 3420, 3300, 3000-
2850, 1730, 1600, 1500, 1160; 
1
H NMR (400 MHz, DMSO-d6)  
0.83 (3H, s, C18H3), 1.0-2.5 (18H, m), 6.53 (1H, d, J = 8.6 Hz, 
C1H), 7.00 (1H, d, J = 8.5 Hz, C2H), 7.30 (2H, AA’BB’, Tosyl), 
7.60 (2H, AA’BB’, Tosyl), and 8.87 (2H, br s, ex. with D2O, NH 
and OH); LRMS (FAB
+
) m/z (%) 440.1 [45, (M+H)
+
], 284.1 
[100, (M-Tosyl)
+
]; LRMS (FAB
-
) m/z (%) 592.2 [10, (M+NBA)
-
], 438.2 [100, (M-H)
-
]; HRMS (FAB
+
) Found: 440.1881. 
C25H30NO4S requires 440.1896. Found: C, 68.2; H, 6.74; N, 3.24. 
C25H29NO4S requires C, 68.31; H, 6.65; N, 3.19%. 
 
5.3.39.  Estra-1,3,5(10)-trien-17-oxo[4,3d]-1,2,3-
oxathiazole-3-tosyl-2,2-dioxide (23c) 
 Sulfuryl chloride (2.0 mL of a 0.5 M solution in 
dichloromethane, 1.00 mmol) was added dropwise with stirring 
over a 5 min period to 23b (400 mg, 910 mol) and triethylamine 
(0.39 mL, 2.73 mmol) in dichloromethane (20 mL) at ice-water 
temperature under an atmosphere of nitrogen.  After an additional 
15 min, the reaction mixture was allowed to warm to room 
temperature, concentrated and diluted with ethyl acetate (50 mL).  
The organic layer was washed with hydrochloric acid (1M, 100 
mL) followed by brine (4 x 50 mL), dried (MgSO4), filtered and 
evaporated to give a light yellow residue/syrup (550 mg) which 
was fractionated by flash chromatography (chloroform/acetone, 
16:1). The first fraction that isolated upon evaporation gave 23c 
as a creamy residue (312 mg). Mp 105–115
o
C; Rf (chloroform/ 
acetone, 8:1) 0.69, c.f. Rf 0.48 (23b); 
1
H NMR (400 MHz, 
CDCl3)  0.98 (3H, s, C18H3), 1.4-2.4 (m), 2.45 (3H, s, ArCH3), 
2.5-2.6 (~1H, m), 3.20 (1H, m), 3.35 (1H, m), 6.86 (1H, d, J = 
8.5 Hz, ArH), 7.24 (2H, AA’BB’, Tosyl), 7.34 (1H, d, J = 8.5 
Hz, ArH), 7.51 (2H, AA’BB’, Tosyl); LRMS (FAB
+
) m/z (%) 
879.6 (20), 599.4 (40), 337.2 (15), 91.0 (100); LRMS (FAB
-
) m/z 
(%) 346.1 [100, (M-Tosyl)
-
].  This fraction was used for the next 
reaction without further purification. 
 
5.3.40.  Estra-1,3,5(10)-trien-17-oxo[4,3d]-1,2,3-
oxathiazole-2,2-dioxide (23) 
 To a solution of crude 23c (150 mg, 299 mol) in acetonitrile 
(20 mL) was added a solution of potassium fluoride (56 mg, 964 
mol) in water (5 mL).  The resulting mixture was refluxed for 4 
h, cooled, concentrated and diluted with ethyl acetate (50 mL). 
The organic layer was washed with hydrochloric acid (1M, 50 
mL) followed by brine (4 x 50 mL).  After drying (MgSO4) and 
filtration, the filtrate on evaporation gave a yellow-green syrup 
(170 mg) which was fractionated by flash chromatography (ethyl 
acetate/hexane, 1:1 to 4:1 gradient) to give a green residue (95 
mg). A solution of this fraction in absolute ethanol was heated 
with activated charcoal and upon filtration and evaporation gave 
23 as a creamy powder (85 mg, 245 mol, 82%); IR max/cm
-1
 
(KBr) 3300-3000, 3000-2850, 1710, 1450, 1370, 1190; 
1
H NMR 
(400 MHz, CDCl3)  0.93 (3H, s, C18H3), 1.2-2.8 (~15H, m), 
6.73 (1H, br s, NH), 6.94 (1H, d, J = 8.5 Hz, ArH) and 7.07 (1H, 
d, J = 8.5 Hz, ArH); LRMS (FAB
+
) m/z (%) 879.6 (50), 599.3 
(100), 530.3 (20), 337.2 (30), 263.2 (24), 219.1 (20), 97.0 (55); 
LRMS (FAB
-
) m/z (%) 1086.0 (10), 346.1 [100, (M-H)
-
], 297.2 
(25); HRMS (FAB-) Found: 346.1128. C18H20NO4S requires 
346.1113. HPLC: Waters “Symmetry” C18 (packing: 3.5 m, 4.6 
x 150 mm); mobile phase MeCN/H2O (96/4) isocratic; flow rate, 
1 mL/min; tR = 1.20 min; purity: >98%.  
 
Acknowledgements 
We thank A. C. Smith for technical assistance. This work was 
supported by Sterix Ltd. 
 
References 
1. Adams, J. B.; Garcia, M.; Rochefort, H. Cancer Res. 1981, 
41, 4720.    
2. Dauvois, S.; Labrie, F. Breast Cancer Res. Treat. 1989, 13, 
61.    
3. Naitoh, K.; Honjo, H; Yamamoto, T.; Urabe, M.; Ogino, Y.; 
Yasumura, T.; Nambara, T. J. Steroid Biochem. 1989, 33, 
1049.    
4. Chetrite, G. S.; Cortes-Prieto, J.; Philippe, J. C.; Wright, F.; 
Pasqualini, J. R. J. Steroid Biochem. Mol. Biol. 2000, 72, 23. 
5. Anderson, C. J.; Lucas, L. J. H.; Widlanski, T. S. J. Am. 
Chem. Soc. 1995, 117, 3889. 
6. Nussbaumer, P.; Billich, A. Med. Res. Rev. 2004, 24, 529. 
7. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Newman, S. P.; Potter, 
B. V. L. Endocr. Rev.2005, 26, 171. 
8. Woo, L. W. L.; Purohit, A.; Potter, B. V. L. Mol. Cell. 
Endocr. 2011, 340, 175. 
9. Maltais, R.; Poirier, D. Steroids 2011, 76, 929. 
10. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. J. 
Med. Chem. 1994, 37, 219. 
11. Fischer, D. S. ; Woo, L. W. L. ; Mahon,  M. F. ; Purohit, A. ; 
Reed, M. J. ; Potter, B. V. L. Bioorg. Med. Chem. 2003, 11, 
1685. 
12. Purohit, A.; Williams, G. J.; Roberts, C. J.; Potter, B. V. L.; 
Reed, M. J. Int. J. Cancer 1995, 63, 106. 
13. Elger, W.; Schwarz, S.; Hedden, A.; Reddersen, G.; 
Schneider, B. J Steroid Biochem. Mol. Biol. 1995, 55, 395. 
14. Elger, W.; Barth, A.; Hedden, A.; Redderse, G.; Ritter, P.; 
Schneider, B.; Zuchner, J.; Krahl, E.; Muller, K.; Oettel, M.; 
Schwarz, S. Reprod. Fertil. Dev. 2001, 13, 297. 
15. Chander, S. K.; Purohit, A.; Woo, L. W. L.; Potter, B. V. L.; 
Reed, M. J. Biochem. Biophys. Res. Comm. 2004, 322, 217. 
16. Colette, S.; Defrère, S.; Lousse, J. C.; Van Langendonckt, 
A.; Gotteland, J. P.; Loumaye, E.; Donnez,  Hum. Reprod. 
2011, 26, 1362. 
17. Tomson, A. J.; Horwitz, J. P. J. Org. Chem. 1959, 24, 2056. 
18. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; 
Potter, B. V. L. J. Steroid Biochem. Mol. Biol. 1996, 57, 79. 
19. Patton, T. L. J. Org. Chem. 1962, 27, 910. 
20. Bulman Page, P. C., Hussain, F., Maggs, J. L., Morgan, P., 
Park, B. K. Tetrahedron 1990, 46, 2059. 
21. Slaunwhite Jr., W. R.; Neely, L. J. Org. Chem. 1962, 27, 
1749. 
22. Huang, M-L. J. Am. Chem. Soc. 1949, 71, 3301. 
23. Andersen, K. K.; Bray, D. D.; Chumpradit, S.; Clark, M. E.; 
Habgood, G. J.; Hubbard, C. D.; Young, K. M. J. Org. 
Chem. 1991, 56, 6508.   
24. Andersen, K. K.; Kociolek, M. G. J. Org. Chem. 1995, 60, 
2003. 
25. Kraychy, S. J. Am. Chem. Soc. 1959, 81, 1702. 
26. Kurita, K. Chem. Ind. 1974, 345. 
27. Purohit, A.; Vernon, K. A.; Hummelinck, A. E. W.; Woo, L. 
W. L.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J. J. 
Steroid Biochem. Mol. Biol. 1998, 64, 269. 
28. Reed, J. E.; Woo, L. W. L.; Robinson, J. J.; Leblond, B.; 
Leese, M. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 
Biochem. Biophy. Res. Comm. 2004, 317, 169. 
29. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Potter, B. V. L. 
Endocrine-related. Cancer, 1996, 3, 9. 
30. Woo, L. W. L.; Sutcliffe, O. B.; Bubert, C.; Grasso, A.; 
Chander, S. K.; Purohit, A.; Reed, M. J., Potter, B. V. L. J. 
Med. Chem. 2003. 46, 3193. 
31. Woo, L. W. L.; Bubert, C.; Sutcliffe, O. B.; Smith, A.; 
Chander, S. K.; Mahon, M. F.; Purohit, A.; Reed, M. J.; 
Potter, B. V. L. J. Med. Chem. 2007, 50, 3540. 
32. Jackson, T.; Woo, L. W. L.; Trusselle, M. N.; Chander, S. 
K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Org. Biomol. 
Chem. 2007, 5, 2940. 
33. Bubert, C.; Woo, L. W. L.; Sutcliffe, O. B.; Mahon, M. F.; 
Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 
ChemMedChem 2008, 3, 1708. 
34. Wood, P. M.; Woo, L. W. L.; Humphreys, A.; Chander, S. 
K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. J. Steroid 
Biochem. Mol. Biol. 2005, 94, 123. 
35. Wood, P. M.; Woo, L. W. L.; Labrosse; J-R., Thomas, M. 
P.; Mahon, M. F.; Chander, S. K.; Purohit, A.; Reed, M. J.; 
Potter, B. V. L. ChemMedChem 2010, 5, 1577. 
36. Wood, P. M.; Woo, L. W. L.; Thomas, M. P.; Mahon, M. F.; 
Purohit, A.; Potter, B. V. L. ChemMedChem 2011, 6, 1423. 
37. Woo, L. W. L.; Jackson, T.; Putey, A.; Cozier; G., Leonard, 
P.; Acharya, K. R.; Chander, S. K.; Purohit, A.; Reed, M. J.; 
Potter, B. V. L. J. Med. Chem. 2010, 53, 2155. 
38. Woo, L. W. L.; Bubert, C.; Purohit, A.; Potter, B. V. L. ACS 
Med. Chem. Lett. 2011, 2, 243. 
39. Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L. J 
Med. Chem. 1996, 39, 1349. 
40. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, 
B. V. L. Chem. Bio. 2000, 7, 773. 
41. Woo, L. W. L.; Ganeshapillai, D.; Thomas, M.; Sutcliffe, O. 
B.; Malini, B.; Mahon, M. F.; Purohit, A.; Potter, B. V. L. 
ChemMedChem 2011, 6, 2019. 
42. Phan, C-M.; Liu, Y.; Kim, B-M.; Mostafa, Y.; Taylor, S. D. 
Bioorg. Med. Chem. 2011, 19, 5999. 
43. Lu, Y.; Shi, T.; Wang, Y.; Yang, H; Yan, X.; Luo, X.; Jiang, 
H.; Zhu, W. J. Med. Chem. 2009, 52, 2854. 
44. Patani, G. A.; LaVoie, E. J. Chem. Rev. 1996, 96, 3147. 
45. Woo, L. W. L.; Leese, M. P.; Leblond, B.; Purohit, A.; 
Wood, L.; Packham, G.; Robinson, J. J.; Vicker, N.; Reed, 
M. J.; Potter, B. V. L. Eur. J. Cancer 2002, 38 (Suppl. 7), 
S125. 
46. Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 
Bioorg. Med. Chem. Lett. 1997, 7, 3075. 
47. Appel, R.; Berger, G. Chem. Ber. 1958, 91, 1339. 
48. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; 
Potter, B. V. L. J. Steroid Biochem. Mol. Biol. 1996, 57, 79. 
49. Purohit, A.; Williams, G. J.; Howarth, N. M.; Potter, B. V. 
L.; Reed, M. J. Biochemistry 1995, 34, 11508. 
50. Duncan, L.; Purohit, A.; Howarth, N. M.; Potter, B. V. L.; 
Reed, M. J. Cancer Res. 1993, 53, 298. 
 
